Radon,O
et,O
al,O
.,O
BMC,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
STUDY,O
PROTOCOL,O
Open,O
Access,O
Proto,O
‐,O
col,O
of,O
a,O
population,O
‐,O
based,O
prospective,O
COVID,O
‐,O
19,NUMBER
cohort,O
study,O
Mu,O
‐,O
nich,O
.,O
Germany,COUNTRY
Katja,LOCATION
Radon1,O
.2,O
*,O
.,O
Elmar,PERSON
Saathoff3,O
.4,O
.,O
Michael,PERSON
Pritsch3,O
.,O
Jessica,PERSON
Michelle,PERSON
Guggenbhl,PERSON
Noller3,PERSON
.,O
Inge,PERSON
Kroidl3,O
.4,O
.,O
Laura,PERSON
Olbrich3,PERSON
.,O
Verena,PERSON
Thiel3,PERSON
.,O
Max,PERSON
Diefenbach3,PERSON
.,O
Friedrich,PERSON
Riess3,PERSON
.,O
Felix,PERSON
Forster1,PERSON
.,O
Fabian,PERSON
Theis5,O
.6,O
.,O
Andreas,PERSON
Wieser3,O
.7,O
.,O
Michael,PERSON
Hoelscher2,O
.3.4,O
and,O
the,O
KoCo19,O
collaboration,O
group,O
Background,O
:,O
Due,O
to,O
the,O
SARS,MISC
‐,O
CoV,O
‐,O
2,NUMBER
pandemic,O
.,O
public,O
health,O
interventions,O
have,O
been,O
introduced,O
globally,O
in,O
order,O
to,O
prevent,O
the,O
spread,O
of,O
the,O
virus,O
and,O
avoid,O
the,O
overload,O
of,O
health,O
care,O
systems,O
.,O
especially,O
for,O
the,O
most,O
severely,O
affected,O
patients,O
.,O
Scientific,O
studies,O
to,O
date,O
have,O
focused,O
primarily,O
on,O
describing,O
the,O
clinical,O
course,O
of,O
patients,O
.,O
identifying,O
treatment,O
options,O
and,O
developing,O
vaccines,O
.,O
In,O
Ger,O
‐,O
many,O
.,O
as,O
in,O
many,O
other,O
regions,O
.,O
current,DATE
tests,O
for,O
SARS,O
‐,O
CoV2,O
are,O
not,O
conducted,O
on,O
a,O
representative,TITLE
basis,O
and,O
in,O
a,O
longitudinal,O
de,O
‐,O
sign,O
.,O
Furthermore,O
.,O
knowledge,O
about,O
the,O
immune,O
status,O
of,O
the,O
popu,O
‐,O
lation,O
is,O
lacking,O
.,O
Nonetheless,O
.,O
these,O
data,O
are,O
needed,O
to,O
under,O
‐,O
stand,O
the,O
dynamics,O
of,O
the,O
pandemic,O
and,O
hence,O
to,O
appropriately,O
de,O
‐,O
sign,O
and,O
evaluate,O
interventions,O
.,O
For,O
this,O
purpose,O
.,O
we,O
recently,DATE
started,O
a,O
prospective,O
population,O
‐,O
based,O
cohort,O
in,O
Munich,CITY
.,O
Germany,COUNTRY
.,O
with,O
the,O
aim,O
to,O
develop,O
a,O
better,O
understanding,O
of,O
the,O
state,O
and,O
dynamics,O
of,O
the,O
pandemic,O
.,O
Methods,O
:,O
In,O
100,NUMBER
out,O
of,O
755,NUMBER
randomly,O
selected,O
constituencies,O
.,O
3000,NUMBER
Munich,CITY
households,O
are,O
identified,O
via,O
random,O
route,O
and,O
offered,O
enrollment,O
into,O
the,O
study,O
.,O
All,O
household,O
members,O
are,O
asked,O
to,O
complete,O
a,O
baseline,O
questionnaire,O
and,O
subjects,O
14,DURATION
years,DURATION
of,O
age,O
are,O
asked,O
to,O
provide,O
a,O
venous,O
blood,O
sample,O
of,O
3,NUMBER
ml,O
for,O
the,O
determination,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
IgG,O
/,O
IgA,O
sta,O
‐,O
tus,O
.,O
The,O
residual,O
plasma,O
and,O
the,O
blood,O
pellet,O
are,O
preserved,O
for,O
later,O
genetic,O
and,O
molecular,O
biological,O
investigations,O
.,O
For,O
twelve,NUMBER
months,DURATION
.,O
each,O
household,O
member,O
is,O
asked,O
to,O
keep,O
a,O
diary,O
of,O
daily,SET
symptoms,O
.,O
whereabouts,O
and,O
contacts,O
via,O
WebApp,O
.,O
If,O
symptoms,O
sug,O
‐,O
gestive,O
for,O
COVID,O
‐,O
19,NUMBER
are,O
reported,O
.,O
family,O
members,O
.,O
including,O
children,O
<,O
14,DURATION
years,DURATION
.,O
Munich,CITY
.,O
for,O
molecular,O
testing,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
In,O
case,O
of,O
severe,O
symptoms,O
.,O
participants,O
will,O
be,O
trans,O
‐,O
ferred,O
to,O
a,O
Munich,CITY
hospital,O
.,O
For,O
one,DURATION
year,DURATION
.,O
the,O
study,O
teams,O
re,O
‐,O
visits,O
the,O
households,O
for,O
blood,O
sampling,O
every,SET
six,SET
weeks,SET
.,O
Katja,PERSON
Radon,O
and,O
Elmar,PERSON
Saathoff,PERSON
contributed,O
equally,O
to,O
this,O
work,O
.,O
Ziemssenstr,O
.,O
1,NUMBER
.,O
80336,NUMBER
Munich,CITY
.,O
Germany,COUNTRY
which,O
permits,O
use,O
.,O
sharing,O
.,O
adaptation,O
.,O
distribution,O
and,O
reproduction,O
in,O
any,O
medium,O
or,O
for,O
‐,O
mat,O
.,O
as,O
long,O
as,O
you,O
give,O
licence,O
and,O
your,O
intended,O
use,O
is,O
not,O
permitted,O
by,O
statutory,O
regulation,O
or,O
exceeds,O
the,O
permitted,O
use,O
.,O
you,O
will,O
need,O
to,O
obtain,O
Radon,MISC
et,O
al,O
.,O
BMC,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
Discus,ORGANIZATION
‐,O
sion,O
:,O
With,O
the,O
planned,O
study,O
we,O
will,O
establish,O
a,O
reliable,O
epi,O
‐,O
demiological,O
tool,O
to,O
improve,O
the,O
understanding,O
of,O
the,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
to,O
better,O
assess,O
the,O
effectiveness,O
of,O
public,O
health,O
measures,O
as,O
well,O
as,O
their,O
socio,O
‐,O
economic,O
effects,O
.,O
This,O
will,O
support,O
policy,O
makers,O
in,O
managing,O
the,O
epidemic,O
based,O
on,O
sci,O
‐,O
entific,O
evidence,O
.,O
Keywords,O
:,O
COVID,O
‐,O
19,NUMBER
.,O
Pandemics,O
.,O
Coronavirus,O
in,O
‐,O
fections,O
/,O
epidemiology,O
.,O
Panel,ORGANIZATION
study,O
.,O
Enzyme,O
‐,O
linked,O
Immunosorbent,O
assay,O
.,O
Models,O
.,O
economic,O
.,O
Stress,O
.,O
psychological,O
.,O
Socio,O
‐,O
economic,O
factors,O
.,O
Spatial,O
analysis,O
.,O
Geographic,O
information,O
systems,O
Since,O
the,O
first,ORDINAL
description,O
of,O
the,O
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
December,DATE
2019,DATE
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
the,O
disease,CAUSE_OF_DEATH
has,O
spread,O
world,O
‐,O
wide,O
and,O
classified,O
as,O
a,O
global,O
emergency,O
by,O
the,O
WHO,O
in,O
early,O
2020,DATE
[,O
1,NUMBER
],O
.,O
In,O
Germany,COUNTRY
.,O
the,O
first,ORDINAL
confirmed,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
was,O
registered,O
on,O
January,DATE
6th,DATE
2020,DATE
at,O
the,O
Division,O
of,O
Infectious,O
Dis,O
‐,O
eases,O
and,O
3,NUMBER
],O
.,O
The,O
transmission,O
chains,O
were,O
interrupted,O
by,O
contact,O
tracing,O
and,O
isolation,O
of,O
the,O
affected,O
persons,O
.,O
However,O
.,O
due,O
to,O
the,O
return,O
of,O
German,NATIONALITY
tourists,O
from,O
holidays,O
in,O
the,O
high,O
‐,O
risk,O
ar,O
‐,O
eas,O
of,O
northern,O
Italy,COUNTRY
.,O
in,O
connection,O
with,O
a,O
carnival,O
celebration,O
in,O
the,O
district,O
of,O
Heinsberg,LOCATION
(,O
60,NUMBER
km,O
west,O
of,O
Cologne,CITY
),O
.,O
the,O
virus,O
spread,O
to,O
13,NUMBER
of,O
16,NUMBER
federal,O
states,O
within,O
one,DURATION
month,DURATION
[,O
4,NUMBER
],O
.,O
The,O
expo,O
‐,O
nential,O
increase,O
in,O
newly,O
confirmed,O
cases,O
in,O
Germany,COUNTRY
reached,O
a,O
total,O
of,O
155.193,NUMBER
positively,O
tested,O
cases,O
on,O
April,DATE
27th,DATE
2020,DATE
(,O
187,NUMBER
per,O
100,NUMBER
.,O
000,NUMBER
inhabitants,O
),O
[,O
4,NUMBER
],O
.,O
Simulations,O
and,O
experiences,O
of,O
other,O
countries,O
suggest,O
that,O
healthcare,O
systems,O
would,O
be,O
overbur,O
‐,O
dened,O
and,O
eventually,O
collapse,O
due,O
to,O
a,O
pronounced,O
increase,O
of,O
pa,O
‐,O
tients,O
needing,O
intensive,O
care,O
support,O
if,O
no,O
interventions,O
were,O
implemented,O
[,O
513,NUMBER
],O
.,O
In,O
the,O
absence,O
of,O
vaccinations,O
and,O
specific,O
treatment,O
options,O
.,O
public,O
health,O
interventions,O
were,O
initiated,O
in,O
Germany,COUNTRY
.,O
similarly,O
to,O
numerous,O
other,O
countries,O
comparably,O
affect,O
‐,O
ed,O
.,O
The,O
measures,O
include,O
isolation,O
of,O
confirmed,O
patients,O
.,O
quaran,O
‐,O
tine,O
of,O
their,O
contacts,O
.,O
use,O
of,O
personal,O
protective,O
equipment,O
.,O
so,O
‐,O
cial,O
borders,O
[,O
6,NUMBER
.,O
14,NUMBER
],O
.,O
Prediction,O
models,O
and,O
experiences,O
from,O
countries,O
like,O
South,COUNTRY
Korea,COUNTRY
suggest,O
that,O
combination,O
of,O
these,O
mea,O
‐,O
sures,O
could,O
be,O
effective,O
in,O
combatting,O
the,O
disease,CAUSE_OF_DEATH
[,O
13,NUMBER
.,O
1518,DATE
],O
.,O
However,O
.,O
past,DATE
evidence,O
from,O
other,O
epidemics,O
was,O
not,O
that,O
convinc,O
‐,O
ing,O
with,O
respect,O
to,O
controlling,O
virus,O
spread,O
by,O
social,O
distancing,O
[,O
19,NUMBER
],O
.,O
It,O
remains,O
unclear,O
how,O
comparable,O
previous,O
viral,O
diseases,CAUSE_OF_DEATH
outbreaks,O
are,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
20,NUMBER
],O
.,O
While,O
potentially,O
saving,O
lives,O
and,O
protecting,O
healthcare,O
systems,O
from,O
breakdown,O
.,O
one,NUMBER
has,O
to,O
bear,O
in,O
mind,O
that,O
measures,O
of,O
social,O
distancing,O
can,O
have,O
a,O
devastating,O
impact,O
on,O
national,O
and,O
global,O
economies,O
.,O
healthcare,O
systems,O
.,O
in,O
‐,O
comes,O
of,O
individuals,O
and,O
families,O
(,O
especially,O
those,O
in,O
precarious,O
employment,O
conditions,O
),O
.,O
education,O
(,O
which,O
particularly,O
affects,O
disadvantaged,O
groups,O
),O
and,O
on,O
health,O
and,O
the,O
psychosocial,O
well,O
‐,O
be,O
‐,O
ing,O
of,O
populations,O
[,O
2022,DATE
],O
.,O
Devastating,O
effects,O
seen,O
in,O
high,O
‐,O
in,O
‐,O
come,O
societies,O
will,O
likely,O
be,O
much,O
worse,O
in,O
low,O
and,O
middle,O
income,O
countries,O
[,O
23,NUMBER
],O
.,O
Results,O
of,O
simulation,O
studies,O
existing,O
so,O
far,O
differ,O
considerably,O
.,O
This,O
is,O
partly,O
due,O
to,O
the,O
unknown,O
number,O
of,O
asymptomatic,O
or,O
minimally,O
symptomatic,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
carriers,O
.,O
and,O
thus,O
the,O
number,O
of,O
undetected,O
cases,O
[,O
4,NUMBER
.,O
7,NUMBER
.,O
13,NUMBER
.,O
17,NUMBER
.,O
24,NUMBER
.,O
25,NUMBER
],O
.,O
In,O
addition,O
.,O
the,O
number,O
of,O
confirmed,O
cases,O
depends,O
on,O
access,O
to,O
healthcare,O
.,O
laboratory,O
availability,O
.,O
and,O
on,O
the,O
criteria,O
applied,O
to,O
select,O
the,O
individuals,O
who,O
should,O
be,O
tested,O
.,O
Therefore,O
.,O
the,O
basic,O
and,O
the,O
effective,O
reproduction,O
number,O
can,O
only,O
be,O
very,O
roughly,O
estimated,O
and,O
the,O
hospitalization,O
and,O
mortality,O
rates,O
re,O
‐,O
main,O
to,O
be,O
confirmed,O
.,O
Community,O
cohorts,O
can,O
help,O
to,O
assess,O
the,O
overall,O
spread,O
of,O
infection,CAUSE_OF_DEATH
in,O
the,O
targeted,O
population,O
and,O
thus,O
provide,O
more,O
reliable,O
estimates,O
of,O
the,O
basic,O
and,O
the,O
effective,O
reproduction,O
number,O
.,O
This,O
will,O
help,O
to,O
evaluate,O
the,O
burden,O
on,O
the,O
healthcare,O
system,O
as,O
well,O
as,O
the,O
effectiveness,O
of,O
public,O
health,O
interventions,O
[,O
26,NUMBER
],O
.,O
Aim,O
of,O
KoCo19,O
(,O
prospective,O
Covid,O
‐,O
19,NUMBER
cohort,O
Munich,CITY
),O
With,O
the,O
community,O
‐,O
based,O
household,O
study,O
presented,O
in,O
this,O
paper,O
.,O
we,O
aim,O
to,O
study,O
the,O
sero,O
‐,O
prevalence,O
and,O
‐,O
incidence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
antibodies,O
in,O
a,O
representative,TITLE
household,O
sample,O
of,O
the,O
Munich,CITY
population,O
.,O
With,O
this,O
approach,O
we,O
will,O
provide,O
a,O
constant,O
‐,O
ly,O
updated,O
epidemiological,O
instrument,O
that,O
represents,O
the,O
number,O
of,O
infections,CAUSE_OF_DEATH
that,O
have,O
occurred,O
in,O
the,O
city,O
.,O
The,O
study,O
may,O
also,O
serve,O
as,O
a,O
pilot,TITLE
for,O
studies,O
in,O
other,O
areas,O
of,O
Germany,COUNTRY
and,O
other,O
countries,O
.,O
The,O
following,O
study,O
questions,O
will,O
be,O
addressed,O
:,O
1,NUMBER
),O
Baseline,O
visit,O
What,O
is,O
the,O
SARS,MISC
‐,O
CoV,O
‐,O
2,NUMBER
antibody,O
prevalence,O
in,O
the,O
Munich,CITY
general,TITLE
population,O
?,O
How,O
many,O
of,O
the,O
initially,O
seropositive,O
individuals,O
in,O
the,O
base,O
‐,O
line,O
‐,O
study,O
were,O
previously,DATE
tested,O
by,O
pharyngeal,O
swab,O
and,O
nucleic,O
acid,O
amplification,O
(,O
PCR,O
),O
(,O
positively,O
or,O
negatively,O
),O
and,O
/,O
or,O
had,O
symptoms,O
suggestive,O
for,O
COVID,O
‐,O
19,NUMBER
(,O
yes,O
or,O
no,O
),O
?,O
Radon,O
et,O
al,O
.,O
BMC,O
Public,O
Health,O
What,O
is,O
the,O
distribution,O
of,O
symptom,O
severity,O
in,O
each,O
Design,O
of,O
KoCo19,O
of,O
the,O
groups,O
described,O
above,O
?,O
How,O
high,O
is,O
the,O
risk,O
of,O
infection,CAUSE_OF_DEATH
for,O
other,O
household,O
members,O
if,O
one,NUMBER
person,O
is,O
infected,O
and,O
can,O
household,O
risk,O
factors,O
be,O
identi,O
‐,O
fied,O
?,O
How,O
high,O
is,O
the,O
risk,O
of,O
infection,CAUSE_OF_DEATH
for,O
other,O
inhabitants,O
of,O
the,O
same,O
apartment,O
building,O
if,O
one,NUMBER
person,O
is,O
infected,O
?,O
What,O
are,O
the,O
risk,O
factors,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
The,O
study,O
design,O
of,O
Ko,O
‐,O
Co19,O
is,O
a,O
community,O
‐,O
based,O
prospective,O
cohort,O
study,O
in,O
randomly,O
selected,O
Munich,CITY
households,O
.,O
All,O
members,O
of,O
the,O
selected,O
house,O
‐,O
holds,O
who,O
are,O
eligible,O
and,O
agree,O
to,O
participate,O
(,O
see,O
Study,O
popu,O
‐,O
lation,O
),O
are,O
invited,O
to,O
the,O
following,O
parts,O
of,O
the,O
2,NUMBER
),O
Follow,O
‐,O
up,O
visits,O
Is,O
there,O
a,O
change,O
in,O
antibody,O
titers,O
of,O
those,O
who,O
initially,O
tested,O
positive,O
.,O
which,O
is,O
potentially,O
necessary,O
to,O
discriminate,O
from,O
cross,O
‐,O
reactivity,O
with,O
other,O
corona,O
viruses,O
?,O
How,O
does,O
the,O
spread,O
of,O
the,O
disease,CAUSE_OF_DEATH
develop,O
and,O
what,O
influence,O
do,O
public,O
health,O
measures,O
have,O
on,O
the,O
incidence,O
?,O
What,O
is,O
the,O
impact,O
of,O
individual,O
behaviour,O
on,O
the,O
incidence,O
of,O
infection,CAUSE_OF_DEATH
?,O
Which,O
risk,O
factors,O
are,O
associated,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
What,O
is,O
the,O
socio,O
‐,O
economic,O
impact,O
of,O
the,O
pandemic,O
and,O
the,O
measures,O
to,O
combat,O
it,O
.,O
especially,O
on,O
the,O
em,O
‐,O
ployment,O
situation,O
and,O
psychosocial,O
endpoints,O
?,O
Setting,O
of,O
KoCo19,O
Munich,CITY
.,O
the,O
capital,O
of,O
the,O
Free,LOCATION
State,LOCATION
of,LOCATION
Bavaria,LOCATION
.,O
is,O
located,O
in,O
the,O
southeast,O
of,O
Germany,COUNTRY
.,O
Approximately,O
1.5,NUMBER
million,NUMBER
people,O
live,O
here,O
.,O
9,PERCENT
%,PERCENT
of,O
these,O
are,O
75,DURATION
years,DURATION
and,O
older,O
[,O
27,NUMBER
],O
.,O
The,O
population,O
density,O
is,O
50,NUMBER
inhabitants,O
per,O
ha,O
[,O
27,NUMBER
],O
.,O
There,O
are,O
70,NUMBER
hospital,O
beds,O
(,O
including,O
5,NUMBER
intensive,O
care,O
unit,O
beds,O
),O
and,O
13,NUMBER
doctors,O
for,O
every,O
10.000,NUMBER
inhabitants,O
[,O
27,NUMBER
],O
.,O
After,O
the,O
first,ORDINAL
100,NUMBER
cases,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
were,O
reported,O
in,O
Munich,CITY
by,O
March,DATE
12th,DATE
2020,DATE
.,O
the,O
Bavarian,MISC
2020,DATE
.,O
initially,O
until,O
May,DATE
11,DATE
th,DATE
2020,DATE
.,O
Since,O
the,O
same,O
date,O
.,O
all,O
shops,O
that,O
do,O
not,O
sell,O
the,O
basic,O
needs,O
of,O
the,O
population,O
were,O
closed,O
.,O
Starting,O
on,O
March,DATE
21th,DATE
2020,DATE
.,O
when,O
1288,DATE
infected,O
individuals,O
were,O
reported,O
in,O
Munich,CITY
.,O
curfews,O
were,O
implemented,O
[,O
28,NUMBER
],O
.,O
According,O
to,O
these,O
curfews,O
.,O
people,O
are,O
essentially,O
only,O
allowed,O
to,O
leave,O
the,O
house,O
to,O
go,O
to,O
work,O
.,O
to,O
the,O
doctor,TITLE
.,O
to,O
buy,O
food,O
.,O
for,O
outdoor,O
sport,O
related,O
activities,O
(,O
jogging,O
.,O
walking,O
),O
or,O
to,O
help,O
others,O
who,O
are,O
depending,O
on,O
support,O
.,O
A,O
minimum,O
distance,O
of,O
1.5,NUMBER
m,O
between,O
in,O
‐,O
dividuals,O
must,O
be,O
maintained,O
.,O
1,NUMBER
.,O
Baseline,O
study,O
(,O
1st,ORDINAL
household,O
visit,O
),O
:,O
During,O
the,O
baseline,O
study,O
.,O
personal,O
identifying,O
informa,O
‐,O
tion,O
is,O
collected,O
and,O
stored,O
in,O
a,O
database,O
separately,O
from,O
the,O
remaining,O
questionnaire,O
information,O
.,O
A,O
blood,O
sample,O
is,O
taken,O
from,O
which,O
sero,O
‐,O
prevalences,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
IgG,O
and,O
IgA,O
antibodies,O
are,O
After,O
the,O
household,O
visit,O
.,O
participants,O
are,O
asked,O
to,O
answer,O
an,O
:,O
2,NUMBER
.,O
Daily,SET
diary,O
:,O
Using,O
a,O
web,O
‐,O
based,O
app,O
.,O
participants,O
are,O
asked,O
to,O
fill,O
out,O
a,O
daily,SET
diary,O
on,O
symptoms,O
suggestive,O
of,O
COVID,O
‐,O
19,NUMBER
infec,O
‐,O
tion,O
.,O
whereabouts,O
.,O
and,O
social,O
contacts,O
.,O
Additional,O
questions,O
might,O
be,O
included,O
throughout,O
the,O
follow,O
‐,O
up,O
period,O
.,O
If,O
symptoms,O
of,O
COVID,O
‐,O
19,NUMBER
occur,O
.,O
a,O
pharyngeal,O
swab,O
for,O
PCR,O
testing,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
offered,O
at,O
our,O
division,O
.,O
3,NUMBER
.,O
Follow,O
‐,O
up,O
household,O
visits,O
:,O
Households,O
are,O
revisited,O
every,SET
three,SET
to,SET
six,SET
weeks,SET
for,O
a,O
new,O
blood,O
sample,O
in,O
order,O
to,O
estimate,O
the,O
sero,O
‐,O
incidence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
‐,O
fection,O
.,O
This,O
frequency,O
can,O
be,O
adapted,O
to,O
the,O
current,DATE
necessities,O
of,O
estimated,O
prediction,O
models,O
.,O
The,O
follow,O
‐,O
ups,O
are,O
currently,DATE
planned,O
for,O
up,DURATION
to,DURATION
12,DURATION
months,DURATION
.,O
The,O
study,O
will,O
be,O
terminated,O
if,O
more,O
efficient,O
methods,O
to,O
assess,O
the,O
course,O
of,O
the,O
epidemic,O
are,O
developed,O
or,O
if,O
this,O
no,O
longer,O
appears,O
relevant,O
.,O
KoCo19,O
study,O
population,O
For,O
KoCo19,O
.,O
a,O
representative,TITLE
sample,O
of,O
Munich,CITY
house,O
‐,O
holds,O
(,O
target,O
population,O
),O
is,O
selected,O
by,O
random,O
walk,O
door,O
‐,O
to,O
‐,O
door,O
methodology,O
[,O
29,NUMBER
],O
.,O
For,O
this,O
purpose,O
.,O
100,NUMBER
of,O
the,O
755,NUMBER
Munich,CITY
con,O
‐,O
stituencies,O
were,O
randomly,O
selected,O
using,O
R,O
(,O
The,O
R,O
project,O
),O
.,O
In,O
each,O
of,O
these,O
constituencies,O
.,O
the,O
geographic,O
center,O
is,O
selected,O
as,O
the,O
starting,O
point,O
of,O
the,O
random,O
route,O
using,O
QGIS,O
.,O
From,O
the,O
address,O
closest,O
to,O
this,O
starting,O
point,O
.,O
30,NUMBER
households,O
per,O
con,O
‐,O
stituency,O
will,O
be,O
included,O
in,O
the,O
study,O
according,O
to,O
a,O
fixed,O
al,O
‐,O
gorithm,O
.,O
In,O
the,O
case,O
of,O
apartment,O
buildings,O
.,O
one,NUMBER
household,O
per,O
floor,O
is,O
selected,O
to,O
investigate,O
possible,O
transmission,O
within,O
the,O
building,O
.,O
All,O
household,O
members,O
14,DURATION
years,DURATION
are,O
invited,O
to,O
partici,O
‐,O
pate,O
in,O
KoCo19,O
by,O
donating,O
a,O
maximum,O
of,O
3,NUMBER
ml,O
of,O
blood,O
and,O
to,O
be,O
available,O
for,O
further,O
blood,O
tests,O
every,O
Radon,MISC
et,O
al,O
.,O
BMC,O
Public,O
Health,O
three,DURATION
to,DURATION
six,DURATION
weeks,DURATION
.,O
Participants,O
are,O
informed,O
about,O
their,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
antibody,O
status,O
.,O
Additionally,O
.,O
all,O
household,O
members,O
are,O
asked,O
to,O
complete,O
a,O
daily,SET
questionnaire,O
on,O
their,O
state,O
of,O
health,O
.,O
whereabouts,O
and,O
social,O
contacts,O
using,O
an,O
internet,O
or,O
a,O
smartphone,O
app,O
(,O
WebApp,O
),O
.,O
Persons,O
who,O
do,O
not,O
have,O
a,O
mobile,TITLE
phone,O
or,O
can,O
not,O
operate,O
an,O
App,MISC
will,O
be,O
interviewed,O
by,O
phone,O
.,O
At,O
least,O
one,NUMBER
household,O
member,O
needs,O
to,O
agree,O
to,O
donate,O
blood,O
.,O
while,O
other,O
members,O
can,O
solely,O
participate,O
in,O
the,O
Inclusion,O
criteria,O
are,O
:,O
At,O
the,O
time,DATE
of,O
inclusion,O
in,O
the,O
study,O
(,O
1st,ORDINAL
household,O
visit,O
),O
.,O
at,O
least,O
one,NUMBER
of,O
the,O
household,O
members,O
must,O
be,O
18,DURATION
years,DURATION
and,O
competent,O
to,O
provide,O
written,O
informed,O
consent,O
.,O
Sufficient,O
command,O
of,O
German,NATIONALITY
to,O
understand,O
the,O
participant,O
in,O
‐,O
formation,O
materials,O
for,O
the,O
study,O
and,O
to,O
answer,O
the,O
question,O
‐,O
naires,O
(,O
Note,O
:,O
Due,O
to,O
the,O
urgency,O
of,O
the,O
study,O
.,O
there,O
is,O
no,O
possi,O
‐,O
bility,O
to,O
develop,O
respondent,O
information,O
and,O
multilingual,O
ques,O
‐,O
tionnaires,O
or,O
to,O
recruit,O
multilingual,O
study,O
The,O
households,O
where,O
residents,O
are,O
not,O
present,DATE
at,O
the,O
time,DATE
of,O
the,O
visit,O
of,O
one,NUMBER
of,O
the,O
study,O
teams,O
and,O
do,O
not,O
call,O
to,O
the,O
provided,O
number,O
in,O
order,O
to,O
arrange,O
a,O
baseline,O
visit,O
.,O
individuals,O
who,O
do,O
not,O
give,O
informed,O
consent,O
or,O
do,O
not,O
meet,O
the,O
inclusion,O
criteria,O
will,O
be,O
replaced,O
by,O
the,O
next,O
house,O
on,O
the,O
route,O
for,O
single,O
/,O
two,NUMBER
‐,O
family,O
houses,O
replaced,O
by,O
the,O
next,O
apartment,O
on,O
the,O
same,O
floor,O
in,O
information,O
.,O
In,O
case,O
of,O
absence,O
at,O
the,O
time,DATE
of,O
the,O
information,O
visit,O
.,O
the,O
teams,O
leave,O
information,O
material,O
including,O
a,O
telephone,O
number,O
in,O
order,O
to,O
schedule,O
the,O
baseline,O
visit,O
.,O
In,O
the,O
initial,O
informative,O
visit,O
.,O
teams,O
are,O
accompanied,O
by,O
a,O
police,TITLE
officer,TITLE
;,O
this,O
is,O
consid,O
‐,O
ered,O
helpful,O
to,O
enhance,O
trust,O
in,O
the,O
study,O
in,O
times,O
were,O
report,O
‐,O
edly,O
fraudsters,O
are,O
taking,O
advantage,O
of,O
the,O
exceptional,O
Overall,O
.,O
at,O
least,O
50,NUMBER
field,O
workers,O
working,O
in,O
25,NUMBER
teams,O
of,O
two,NUMBER
are,O
involved,O
in,O
the,O
study,O
.,O
Each,O
team,O
is,O
responsible,O
for,O
150,NUMBER
households,O
in,O
five,NUMBER
constituencies,O
.,O
One,NUMBER
field,O
worker,O
is,O
a,O
medical,O
student,TITLE
with,O
prior,O
.,O
extensive,O
training,O
in,O
infectious,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
control,O
.,O
including,O
blood,O
sampling,O
and,O
pharyngeal,O
swabs,O
in,O
case,O
participants,O
have,O
symptoms,O
suggestive,O
for,O
COVID,O
‐,O
19,NUMBER
within,O
14,NUMBER
‐,O
days,DURATION
prior,O
to,O
this,O
visit,O
.,O
The,O
second,ORDINAL
field,O
worker,O
is,O
responsible,O
for,O
the,O
informed,O
consent,O
and,O
interviews,O
.,O
Teams,O
of,O
field,O
workers,O
are,O
carefully,O
trained,O
in,O
study,O
procedures,O
.,O
data,O
confidentiality,O
.,O
and,O
infection,CAUSE_OF_DEATH
protection,O
and,O
undergo,O
a,O
proficiency,O
test,O
before,O
initiating,O
field,O
work,O
.,O
During,O
the,O
first,ORDINAL
field,O
visits,O
.,O
they,O
are,O
accompanied,O
by,O
a,O
senior,O
medical,O
doctor,TITLE
of,O
the,O
Division,MISC
of,MISC
Infectious,MISC
Diseases,CAUSE_OF_DEATH
and,O
until,O
the,O
physician,TITLE
approves,O
correct,O
handling,O
of,O
all,O
steps,O
of,O
the,O
field,O
work,O
.,O
To,O
further,O
ensure,O
the,O
quality,O
of,O
field,O
work,O
randomly,O
se,O
‐,O
lected,O
households,O
are,O
called,O
and,O
asked,O
about,O
the,O
last,O
study,O
visit,O
and,O
potential,O
problems,O
.,O
In,O
addition,O
.,O
teams,O
will,O
be,O
repeatedly,O
monitored,O
by,O
a,O
senior,O
medical,O
doctor,TITLE
throughout,O
the,O
study,O
.,O
To,O
avoid,O
infection,CAUSE_OF_DEATH
risks,O
through,O
public,O
transport,O
.,O
all,O
teams,O
use,O
rental,O
cars,O
during,O
the,O
field,O
work,O
.,O
This,O
is,O
also,O
helpful,O
for,O
the,O
teams,O
to,O
be,O
able,O
to,O
carry,O
all,O
the,O
necessary,O
material,O
including,O
personal,O
protective,O
and,O
hygiene,O
equipment,O
.,O
the,O
case,O
of,O
apartment,O
buildings,O
.,O
Study,O
instruments,O
:,O
questionnaires,O
Non,O
‐,O
response,O
is,O
recorded,O
and,O
taken,O
into,O
account,O
in,O
the,O
analysis,O
of,O
the,O
response,O
index,O
.,O
Where,O
feasible,O
.,O
basic,O
information,O
(,O
age,O
.,O
sex,O
.,O
type,O
of,O
building,O
),O
and,O
reason,O
of,O
non,O
‐,O
participation,O
are,O
collected,O
for,O
non,O
‐,O
responders,O
in,O
order,O
to,O
assess,O
representativeness,O
of,O
the,O
study,O
population,O
.,O
In,O
addition,O
.,O
participants,O
socioeconomic,O
status,O
.,O
mi,O
‐,O
grant,O
status,O
.,O
sex,O
.,O
and,O
percentage,O
of,O
households,O
with,O
children,O
and,O
single,O
households,O
will,O
be,O
compared,O
to,O
the,O
official,O
statistics,O
of,O
the,O
selected,O
constituencies,O
and,O
of,O
all,O
Munich,CITY
constituencies,O
(,O
Statistical,ORGANIZATION
Office,ORGANIZATION
Munich,ORGANIZATION
),O
.,O
Field,O
work,O
In,O
order,O
to,O
pre,O
‐,O
inform,O
the,O
population,O
about,O
the,O
study,O
and,O
thus,O
.,O
increase,O
response,O
.,O
the,O
study,O
is,O
announced,O
in,O
In,O
addition,O
.,O
field,O
workers,O
visit,O
the,O
se,O
‐,O
lected,O
households,O
before,O
the,O
start,O
of,O
the,O
baseline,O
study,O
to,O
in,O
‐,O
troduce,O
the,O
study,O
.,O
hand,O
out,O
a,O
short,O
leaflet,O
and,O
also,O
the,O
complete,O
Wherever,O
possible,O
.,O
questions,O
were,O
taken,O
from,O
preexisting,O
validat,O
‐,O
ed,O
questionnaire,O
instruments,O
[,O
3033,NUMBER
],O
.,O
As,O
it,O
will,O
be,O
crucial,O
to,O
minimize,O
attrition,O
over,O
time,O
.,O
we,O
minimized,O
the,O
number,O
of,O
ques,O
‐,O
tions,O
without,O
losing,O
important,O
information,O
.,O
The,O
household,O
ques,O
‐,O
tionnaire,O
includes,O
questions,O
about,O
the,O
living,O
situation,O
(,O
type,O
of,O
housing,O
.,O
number,O
of,O
bedrooms,O
.,O
apartment,O
size,O
),O
.,O
number,O
of,O
inhabi,O
‐,O
tants,O
(,O
including,O
date,O
of,O
birth,O
and,O
sex,O
),O
.,O
highest,O
level,O
of,O
educa,O
‐,O
tion,O
.,O
work,O
situation,O
.,O
household,O
income,O
.,O
second,ORDINAL
hand,O
smoke,O
expo,O
‐,O
sure,O
.,O
work,O
of,O
household,O
members,O
in,O
potentially,O
high,O
risk,O
jobs,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infections,CAUSE_OF_DEATH
.,O
past,DATE
pharyngeal,O
swab,O
testing,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
household,O
members,O
including,O
test,O
results,O
.,O
‐,O
Individual,O
baseline,O
questionnaire,O
Radon,O
et,O
al,O
.,O
BMC,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
At,O
base,O
‐,O
line,O
.,O
all,O
participating,O
household,O
members,O
are,O
asked,O
about,O
date,O
of,O
birth,O
.,O
sex,O
.,O
level,O
of,O
education,O
.,O
employment,O
situation,O
.,O
smoking,CAUSE_OF_DEATH
history,O
.,O
general,TITLE
health,O
.,O
pregnancy,O
.,O
recent,O
influenza,CAUSE_OF_DEATH
vaccination,O
.,O
pre,O
‐,O
existing,O
medical,O
conditions,O
.,O
symptoms,O
suggestive,O
for,O
COVID,O
‐,O
19,NUMBER
in,O
the,DURATION
14,DURATION
days,DURATION
prior,O
to,O
the,O
study,O
.,O
past,DATE
PCR,O
testing,O
of,O
nasopha,O
‐,O
ryngeal,O
samples,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
including,O
test,O
result,O
.,O
use,O
of,O
res,O
‐,O
piratory,O
masks,O
.,O
and,O
work,O
in,O
a,O
potentially,O
high,O
risk,O
job,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
Assuming,O
that,O
each,O
person,O
is,O
included,O
in,O
the,O
study,O
with,O
the,O
same,O
probability,O
.,O
repeated,O
drawing,O
of,O
4500,DATE
from,O
1.5,NUMBER
million,NUMBER
Munich,CITY
residents,O
will,O
yield,O
the,O
95,PERCENT
%,PERCENT
confidence,O
preva,O
‐,O
lence,O
of,O
the,O
total,O
of,O
reported,O
and,O
unreported,O
infections,CAUSE_OF_DEATH
in,O
the,O
baseline,O
survey,O
.,O
The,O
prevalence,O
of,O
confirmed,O
cases,O
was,O
0.3,PERCENT
%,PERCENT
on,O
April,DATE
9th,DATE
2020,DATE
[,O
34,NUMBER
],O
.,O
This,O
shows,O
that,O
the,O
sample,O
size,O
is,O
suffi,O
‐,O
cient,O
for,O
an,O
adequately,O
precise,O
estimate,O
of,O
the,O
actual,O
sero,O
‐,O
prevalence,O
in,O
the,O
baseline,O
survey,O
.,O
Data,O
management,O
The,O
daily,SET
di,O
‐,O
ary,O
includes,O
items,O
about,O
symptoms,O
suggestive,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
social,O
contacts,O
.,O
whereabouts,O
and,O
use,O
of,O
public,O
transport,O
in,O
the,DATE
past,DATE
24,NUMBER
h.,O
Further,O
questions,O
on,O
e.g.,O
.,O
the,O
psychosocial,O
and,O
economic,O
situ,O
‐,O
ation,O
.,O
such,O
as,O
perceived,O
health,O
status,O
.,O
behavioral,O
aspects,O
.,O
or,O
employment,O
and,O
income,O
will,O
be,O
added,O
over,O
the,O
time,O
of,O
the,O
study,O
.,O
and,O
collected,O
e.g.,O
once,DATE
a,DURATION
week,DURATION
.,O
Laboratory,O
analyses,O
Samples,O
will,O
be,O
analyzed,O
and,O
stored,O
at,O
the,O
Division,O
of,O
First,ORDINAL
.,O
blood,O
is,O
sampled,O
in,O
2.7,NUMBER
ml,O
EDTA,O
containers,O
and,O
thoroughly,O
mixed,O
.,O
Samples,O
are,O
indi,O
‐,O
vidually,O
barcoded,O
and,O
packed,O
to,O
be,O
transported,O
to,O
the,O
laboratory,O
ion,O
ice,O
.,O
There,O
.,O
the,O
samples,O
are,O
centrifuged,O
to,O
separate,O
the,O
cell,O
pellet,O
from,O
the,O
remaining,O
plasma,O
.,O
Cell,O
pellets,O
are,O
frozen,O
at,O
80,NUMBER
C,O
for,O
further,O
analysis,O
.,O
while,O
the,O
plasma,O
is,O
used,O
for,O
ELISA,O
analy,O
‐,O
sis,O
using,O
a,O
semi,O
‐,O
automated,O
robotic,O
system,O
(,O
Euroanalyzer,O
I,O
.,O
Eu,O
‐,O
roimmune,O
.,O
Lbeck,LOCATION
.,O
Germany,COUNTRY
),O
.,O
Serology,O
is,O
performed,O
primarily,O
using,O
the,O
Anti,O
‐,O
SARSCov,O
‐,O
2,NUMBER
‐,O
ELISA,O
IgG,O
and,O
IgA,O
(,O
Euroimmune,O
.,O
Lbeck,PERSON
.,O
Ger,O
‐,O
many,O
),O
.,O
The,O
ELISA,O
system,O
has,O
a,O
combined,O
sensitivity,O
of,O
between,O
66.7,PERCENT
%,PERCENT
(,O
<,O
10,DURATION
days,DURATION
after,O
onset,O
of,O
symptoms,O
),O
and,O
100,PERCENT
%,PERCENT
(,O
>,O
10,DURATION
days,DURATION
af,O
‐,O
ter,TITLE
onset,O
of,O
symptoms,O
),O
according,O
to,O
the,O
manufacturer,TITLE
.,O
Specificity,O
is,O
rated,O
as,O
98.5,PERCENT
%,PERCENT
.,O
tested,O
in,O
larger,O
cohorts,O
of,O
blood,O
donors,O
.,O
The,O
remaining,O
plasma,O
is,O
stored,O
for,O
further,O
analysis,O
or,O
confirmatory,O
testing,O
e.g.,O
with,O
virus,O
neutralization,O
as,O
appropriate,O
.,O
Pharyn,O
‐,O
geal,O
swabs,O
are,O
taken,O
using,O
eSwab,O
systems,O
.,O
The,O
samples,O
are,O
stored,O
at,O
4,NUMBER
C,O
and,O
immediately,O
transported,O
to,O
the,O
laboratory,O
.,O
There,O
.,O
RNA,O
extraction,O
is,O
performed,O
.,O
Extracted,O
RNA,O
is,O
divided,O
to,O
allow,O
for,O
cryo,O
‐,O
conservation,O
at,O
80,NUMBER
C,O
as,O
well,O
as,O
for,O
diagnostic,O
RT,O
‐,O
PCR,O
for,O
SARSCoV,O
‐,O
2,NUMBER
.,O
The,O
reserve,O
sample,O
will,O
be,O
used,O
for,O
virus,O
sequence,O
analysis,O
to,O
perform,O
cluster,O
and,O
outbreak,O
analysis,O
and,O
to,O
study,O
within,O
family,O
transmission,O
.,O
Statistical,O
analysis,O
Sample,O
size,O
calculation,O
As,O
an,O
initial,O
number,O
of,O
participants,O
.,O
3000,NUMBER
households,O
with,O
approx.,O
1.5,NUMBER
participants,O
each,O
were,O
calculated,O
.,O
Hospital,O
Mu,O
‐,O
nich,O
.,O
The,O
pseudonymized,O
databases,O
will,O
be,O
combined,O
using,O
a,O
unique,O
participant,O
ID,STATE_OR_PROVINCE
.,O
Using,O
the,O
combined,O
raw,O
data,O
.,O
a,O
scripted,O
routine,O
analysis,O
is,O
used,O
to,O
produce,O
a,O
daily,SET
update,O
of,O
descriptive,O
and,O
bi,O
‐,O
variate,O
prevalence,O
and,O
incidence,O
data,O
to,O
generate,O
a,O
study,O
dash,O
‐,O
board,O
(,O
The,O
R,O
project,O
),O
.,O
Main,O
outcome,O
variables,O
are,O
the,O
prevalence,O
and,O
incidence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
antibodies,O
as,O
well,O
as,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
symptoms,O
in,O
the,O
study,O
population,O
and,O
the,O
dynamics,O
thereof,O
.,O
Main,O
exposure,O
variables,O
are,O
socio,O
‐,O
economic,O
factors,O
.,O
social,O
contacts,O
.,O
city,O
district,O
as,O
well,O
as,O
the,O
living,O
situation,O
.,O
In,O
addition,O
.,O
changes,O
in,O
the,O
non,O
‐,O
pharmaceutical,O
public,O
health,O
interventions,O
will,O
be,O
used,O
as,O
predictor,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
incidence,O
.,O
Descriptive,O
analyses,O
Initial,O
descriptive,O
data,O
analyses,O
will,O
be,O
weighted,O
for,O
cluster,O
sampling,O
and,O
include,O
the,O
following,O
parameters,O
:,O
Description,O
of,O
basic,O
data,O
for,O
responder,O
and,O
non,O
‐,O
responder,O
households,O
Socio,O
‐,O
demographic,O
data,O
and,O
known,O
risk,O
factors,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
‐,O
fection,O
Baseline,O
prevalence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
sero,O
‐,O
positivity,O
in,O
the,O
Munich,CITY
general,TITLE
population,O
stratified,O
for,O
a,O
),O
symptomatic,O
and,O
asymptomatic,O
cases,O
and,O
b,O
),O
cases,O
previously,DATE
tested,O
via,O
PCR,O
The,O
temporal,O
course,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
sero,O
‐,O
positivity,O
in,O
the,O
Munich,CITY
general,TITLE
population,O
(,O
point,O
prevalence,O
and,O
incidence,O
),O
stratified,O
for,O
symptomatic,O
and,O
asymptomatic,O
subjects,O
.,O
and,O
reported,O
cases,O
The,O
daily,SET
prevalence,O
and,O
incidence,O
of,O
possible,O
COVID,O
‐,O
19,NUMBER
symptoms,O
in,O
the,O
study,O
population,O
Bi,O
‐,O
variable,O
and,O
multi,O
‐,O
variable,O
analyses,O
Subsequent,O
bi,O
‐,O
and,O
multivariable,O
analyses,O
.,O
taking,O
cluster,O
sam,O
‐,O
pling,O
into,O
account,O
.,O
will,O
include,O
the,O
following,O
Identification,O
of,O
risk,O
factors,O
for,O
asymptomatic,O
.,O
mildly,O
sympto,O
‐,O
matic,O
and,O
severely,O
symptomatic,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Radon,O
et,O
al,O
.,O
BMC,O
Public,O
Health,O
population,O
(,O
The,O
R,O
Project,O
),O
Assumed,O
true,O
prevalence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
seropositive,O
residents,O
of,O
(,O
1.5,NUMBER
million,NUMBER
inhabitants,O
),O
95,PERCENT
%,PERCENT
Confidence,O
Interval,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
seropositive,O
participants,O
in,O
infections,CAUSE_OF_DEATH
(,O
age,O
.,O
sex,O
.,O
socioeconomic,O
status,O
.,O
occupation,O
.,O
social,O
contacts,O
.,O
district,O
),O
.,O
Prevalence,O
ratios,O
are,O
calculated,O
for,O
this,O
purpose,O
.,O
The,O
temporal,O
relationship,O
of,O
public,O
health,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
symp,O
‐,O
toms,O
and,O
changes,O
in,O
seroprevalence,O
are,O
analysed,O
.,O
e.g.,O
by,O
using,O
mixed,O
effect,O
models,O
with,O
a,O
time,O
varying,O
covariate,O
indicating,O
the,O
different,O
intervention,O
variables,O
at,O
different,O
time,O
points,O
.,O
The,O
effect,O
of,O
discontinuation,O
of,O
public,O
health,O
longitudinally,O
.,O
e.g.,O
by,O
mixed,O
effect,O
models,O
.,O
The,O
interaction,O
between,O
the,O
epidemic,O
and,O
the,O
sociodemographic,O
.,O
economic,O
.,O
psychological,O
variables,O
.,O
and,O
the,O
interventions,O
imple,O
‐,O
mented,O
to,O
contain,O
it,O
.,O
will,O
be,O
An,O
algorithm,O
for,O
the,O
most,O
reliable,O
prediction,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
PCR,O
positivity,O
will,O
be,O
developed,O
.,O
Geo,O
‐,O
spatial,O
modelling,O
of,O
exposures,O
and,O
outcome,O
will,O
be,O
per,O
‐,O
formed,O
.,O
In,O
addition,O
.,O
the,O
data,O
is,O
used,O
to,O
gain,O
knowledge,O
about,O
spread,O
dynamics,O
and,O
to,O
predict,O
the,O
further,O
development,O
of,O
the,O
epidemic,O
under,O
different,O
scenarios,O
.,O
Models,O
used,O
for,O
this,O
purpose,O
are,O
developed,O
throughout,O
the,O
course,O
of,O
the,O
study,O
.,O
The,O
ongoing,O
SARS,O
‐,O
CoV,O
‐,O
19,NUMBER
pandemic,O
has,O
changed,O
daily,SET
life,O
globally,O
to,O
an,O
extent,O
unseen,O
before,O
.,O
Due,O
to,O
the,O
lack,O
of,O
vaccinations,O
and,O
pharmacologi,O
‐,O
cal,O
treatment,O
options,O
.,O
it,O
was,O
predicted,O
that,O
not,O
taking,O
public,O
health,O
action,O
will,O
result,O
in,O
an,O
overload,O
of,O
healthcare,O
systems,O
in,O
most,O
countries,O
and,O
a,O
mortality,O
of,O
millions,O
in,O
the,O
global,O
popula,O
‐,O
tion,O
[,O
25,NUMBER
],O
.,O
The,O
public,O
health,O
interventions,O
that,O
have,O
been,O
recent,O
‐,O
ly,O
implemented,O
by,O
most,O
countries,O
have,O
a,O
huge,O
impact,O
on,O
the,O
econo,O
‐,O
my,O
and,O
most,O
likely,O
.,O
also,O
on,O
health,O
and,O
well,O
‐,O
being,O
of,O
the,O
global,O
population,O
.,O
Therefore,O
.,O
to,O
further,O
understand,O
the,O
dynamics,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
population,O
‐,O
based,O
representative,TITLE
household,O
studies,O
might,O
be,O
helpful,O
and,O
needed,O
.,O
in,O
order,O
to,O
reliably,O
estimate,O
the,O
total,O
number,O
of,O
previously,DATE
infected,O
individuals,O
(,O
with,O
and,O
without,O
symp,O
‐,O
toms,O
),O
.,O
who,O
are,O
hopefully,O
resistant,O
to,O
infection,CAUSE_OF_DEATH
for,O
an,O
extended,O
period,O
of,O
time,O
.,O
The,O
study,O
presented,O
here,O
will,O
provide,O
a,O
first,ORDINAL
estimate,O
of,O
the,O
prevalence,O
and,O
incidence,O
of,O
sero,O
‐,O
positivity,O
in,O
the,O
Munich,CITY
population,O
.,O
Although,O
not,O
generalizable,O
on,O
a,O
global,O
scale,O
.,O
this,O
will,O
give,O
first,ORDINAL
insights,O
about,O
the,O
proportion,O
of,O
asymptomatic,O
and,O
mildly,O
symptomatic,O
carriers,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
comparison,O
to,O
the,O
number,O
of,O
those,O
tested,O
.,O
It,O
will,O
also,O
help,O
to,O
identify,O
risk,O
factors,O
for,O
infection,CAUSE_OF_DEATH
.,O
course,O
of,O
disease,CAUSE_OF_DEATH
and,O
effec,O
‐,O
tiveness,O
and,O
efficiency,O
of,O
the,O
public,O
health,O
measures,O
.,O
Our,O
study,O
has,O
limitations,O
.,O
In,O
the,DATE
last,DATE
years,DATE
.,O
willingness,O
to,O
participate,O
in,O
population,O
‐,O
based,O
studies,O
went,O
down,O
considerably,O
[,O
35,NUMBER
.,O
36,NUMBER
],O
.,O
Low,O
re,O
‐,O
sponse,O
might,O
affect,O
representativeness,O
of,O
the,O
study,O
population,O
.,O
which,O
in,O
turn,O
might,O
have,O
an,O
effect,O
on,O
the,O
generalizability,O
of,O
the,O
prevalence,O
of,O
positive,O
antibody,O
results,O
to,O
the,O
Munich,CITY
source,O
pop,O
‐,O
ulation,O
.,O
However,O
.,O
it,O
is,O
unlikely,O
that,O
participation,O
will,O
depend,O
on,O
sero,O
‐,O
positivity,O
of,O
antibody,O
results,O
as,O
antibody,O
status,O
is,O
un,O
‐,O
known,O
prior,O
to,O
inclusion,O
in,O
the,O
study,O
.,O
In,O
addition,O
.,O
the,O
research,O
topic,O
is,O
of,O
uppermost,O
interest,O
for,O
many,O
citizens,O
in,O
the,O
current,DATE
situation,O
.,O
therefore,O
response,O
is,O
expected,O
to,O
be,O
higher,O
in,O
KoCo19,O
than,O
in,O
other,O
studies,O
.,O
During,O
the,O
first,ORDINAL
recruitment,O
days,DURATION
.,O
an,O
overall,O
response,O
of,O
close,O
to,O
50,PERCENT
%,PERCENT
was,O
reached,O
.,O
this,O
provides,O
evi,O
‐,O
dence,O
for,O
the,O
aforementioned,O
hypothesis,O
.,O
Response,O
will,O
be,O
in,O
‐,O
creased,O
by,O
revisiting,O
households,O
which,O
did,O
not,O
open,O
the,O
door,O
at,O
the,O
first,ORDINAL
visit,O
.,O
For,O
the,O
associations,O
under,O
study,O
.,O
representa,O
‐,O
tiveness,O
is,O
of,O
less,O
concern,O
[,O
37,NUMBER
],O
.,O
However,O
.,O
we,O
might,O
not,O
be,O
able,O
to,O
reach,O
high,O
response,O
especially,O
in,O
specific,O
groups,O
of,O
the,O
tar,O
‐,O
get,O
population,O
.,O
e.g.,O
subjects,O
with,O
migration,O
background,O
as,O
they,O
are,O
generally,O
harder,O
to,O
reach,O
in,O
epidemiological,O
studies,O
[,O
38,NUMBER
],O
and,O
because,O
time,O
constraints,O
impede,O
the,O
development,O
of,O
study,O
docu,O
‐,O
ments,O
in,O
other,O
languages,O
than,O
German,NATIONALITY
at,O
the,O
initiation,O
of,O
the,O
study,O
.,O
Likewise,O
.,O
the,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
varies,O
locally,O
and,O
de,O
‐,O
pends,O
on,O
several,O
factors,O
.,O
such,O
as,O
the,O
time,O
course,O
of,O
the,O
infec,O
‐,O
tion,O
in,O
the,O
respective,O
region,O
.,O
the,O
Radon,MISC
et,O
al,O
.,O
BMC,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
population,O
density,O
and,O
age,O
distribution,O
of,O
the,O
population,O
.,O
the,O
available,O
capacities,O
and,O
the,O
applied,O
countermeasures,O
.,O
Therefore,O
.,O
prevalence,O
and,O
incidence,O
results,O
obtained,O
in,O
this,O
study,O
locally,O
might,O
not,O
be,O
easily,O
generalizable,O
to,O
other,O
cities,O
.,O
regions,O
or,O
countries,O
.,O
Losses,O
‐,O
to,O
‐,O
follow,O
up,O
will,O
likely,O
occur,O
especially,O
when,O
public,O
health,O
interventions,O
are,O
reduced,O
or,O
become,O
less,O
restric,O
‐,O
tive,O
and,O
the,O
public,O
attention,O
focuses,O
less,O
on,O
the,O
pandemic,O
.,O
How,O
‐,O
ever,O
.,O
as,O
long,O
as,O
these,O
missing,O
data,O
can,O
be,O
assumed,O
to,O
be,O
missing,O
at,O
random,O
multiple,O
imputation,O
can,O
account,O
for,O
attrition,O
[,O
39,NUMBER
],O
.,O
With,O
respect,O
to,O
reporting,O
bias,O
.,O
one,NUMBER
may,O
assume,O
that,O
participants,O
are,O
more,O
likely,O
to,O
over,O
‐,O
report,O
symptoms,O
which,O
will,O
result,O
in,O
an,O
overestimation,O
of,O
the,O
symptom,O
prevalence,O
.,O
In,O
order,O
to,O
minimize,O
other,O
forms,O
of,O
reporting,O
bias,O
we,O
use,O
as,O
many,O
items,O
from,O
validated,O
questionnaire,O
instruments,O
as,O
possible,O
.,O
In,O
addition,O
.,O
all,O
items,O
were,O
carefully,O
checked,O
by,O
several,O
members,O
of,O
the,O
KoCo,O
‐,O
19,NUMBER
team,O
for,O
their,O
face,O
validity,O
.,O
Questionnaires,O
.,O
especially,O
the,O
daily,SET
diary,O
.,O
were,O
kept,O
as,O
short,O
as,O
possible,O
.,O
Therefore,O
.,O
the,O
study,O
might,O
not,O
be,O
able,O
to,O
answer,O
specific,O
questions,O
in,O
favour,O
of,O
more,O
valid,O
answers,O
and,O
low,O
attrition,O
rate,O
over,O
time,O
.,O
For,O
such,O
aspects,O
.,O
case,O
‐,O
control,O
studies,O
.,O
potentially,O
nested,O
in,O
the,O
current,DATE
study,O
.,O
could,O
be,O
per,O
‐,O
formed,O
.,O
For,O
ethical,O
reasons,O
.,O
participants,O
will,O
receive,O
their,O
SARSCoV,O
‐,O
2,NUMBER
antibody,O
status,O
after,O
each,O
blood,O
sampling,O
.,O
This,O
might,O
influence,O
their,O
subsequent,O
behaviour,O
.,O
especially,O
when,O
antibody,O
status,O
is,O
positive,O
.,O
To,O
minimize,O
social,O
desirability,O
bias,O
.,O
ques,O
‐,O
tionnaires,O
are,O
web,O
‐,O
based,O
and,O
are,O
completed,O
by,O
the,O
participants,O
themselves,O
.,O
However,O
.,O
because,O
not,O
all,O
participants,O
might,O
have,O
web,O
‐,O
access,O
and,O
especially,O
older,O
participants,O
might,O
not,O
have,O
the,O
nec,O
‐,O
essary,O
internet,O
competencies,O
.,O
a,O
telephone,O
interview,O
),O
is,O
recorded,O
so,O
that,O
systematic,O
differences,O
in,O
response,O
can,O
be,O
accounted,O
for,O
.,O
We,O
are,O
not,O
able,O
to,O
include,O
children,O
under,O
the,O
age,O
of,O
14,DURATION
years,DURATION
from,O
the,O
beginning,O
mainly,O
due,O
to,O
ethical,O
concerns,O
regarding,O
the,O
venous,O
blood,O
sampling,O
by,O
a,O
medical,O
student,TITLE
.,O
Over,O
the,O
course,O
of,O
the,O
study,O
development,O
of,O
other,O
test,O
methods,O
might,O
allow,O
the,O
in,O
‐,O
clusion,O
of,O
this,O
important,O
part,O
of,O
the,O
Random,MISC
route,O
recruitment,O
is,O
a,O
feasible,O
way,O
of,O
recruitment,O
where,O
population,O
lists,O
do,O
not,O
exist,O
or,O
are,O
hard,O
to,O
obtain,O
.,O
It,O
has,O
been,O
applied,O
by,O
the,O
WHO,ORGANIZATION
in,O
various,O
vaccination,O
studies,O
since,O
the,DATE
1980s,DATE
.,O
was,O
modified,O
over,O
time,O
and,O
it,O
is,O
also,O
used,O
in,O
large,O
scale,O
community,O
surveys,O
such,O
as,O
the,O
Eu,O
‐,O
ropean,O
Working,O
Condition,O
Survey,O
[,O
29,NUMBER
.,O
40,NUMBER
],O
.,O
The,O
alternative,O
ap,O
‐,O
proach,O
.,O
sampling,O
via,O
the,O
Munich,CITY
population,O
registry,O
.,O
would,O
have,O
taken,O
more,O
time,O
due,O
to,O
the,O
formal,O
requirements,O
and,O
thus,O
would,O
have,O
slowed,O
down,O
the,O
start,O
of,O
the,O
study,O
.,O
As,O
we,O
apply,O
a,O
cluster,O
sampling,O
approach,O
(,O
100,NUMBER
out,O
of,O
755,NUMBER
constituencies,O
),O
and,O
include,O
more,O
than,O
one,NUMBER
person,O
per,O
household,O
and,O
more,O
than,O
one,NUMBER
subject,O
per,O
apartment,O
building,O
.,O
clustering,O
has,O
to,O
be,O
taken,O
into,O
account,O
in,O
the,O
statistical,O
analyses,O
.,O
Using,O
constituencies,O
made,O
inclusion,O
of,O
3000,NUMBER
households,O
and,O
the,O
follow,O
‐,O
up,O
visits,O
within,O
six,DURATION
weeks,DURATION
feasi,O
‐,O
ble,O
.,O
Inclusion,O
of,O
more,O
than,O
one,NUMBER
household,O
member,O
and,O
one,NUMBER
house,O
‐,O
hold,O
per,O
floor,O
will,O
help,O
us,O
to,O
better,O
understand,O
the,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
within,O
households,O
and,O
apartment,O
buildings,O
.,O
In,O
addi,O
‐,O
tion,O
.,O
inclusion,O
of,O
more,O
than,O
one,NUMBER
household,O
per,O
apartment,O
building,O
takes,O
into,O
account,O
that,O
larger,O
number,O
of,O
inhabitants,O
live,O
in,O
apartment,O
buildings,O
.,O
than,O
in,O
one,NUMBER
‐,O
or,O
two,NUMBER
‐,O
family,O
houses,O
.,O
which,O
would,O
otherwise,O
have,O
been,O
overrepresented,O
.,O
The,O
sample,O
size,O
cal,O
‐,O
culation,O
reported,O
here,O
did,O
not,O
take,O
clustering,O
into,O
account,O
.,O
This,O
was,O
due,O
to,O
the,O
fact,O
that,O
the,O
prevalence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
within,O
clusters,O
(,O
household,O
.,O
apartment,O
building,O
.,O
constituency,O
),O
is,O
so,O
far,O
unknown,O
.,O
Taking,O
a,O
more,O
conservative,IDEOLOGY
approach,O
of,O
considering,O
only,O
3000,NUMBER
participants,O
(,O
=,O
number,O
of,O
households,O
),O
instead,O
of,O
4500,NUMBER
par,O
‐,O
ticipants,O
.,O
the,O
95,PERCENT
%,PERCENT
Confidence,O
Interval,O
for,O
a,O
given,O
prevalence,O
of,O
0.5,PERCENT
%,PERCENT
(,O
50,PERCENT
%,PERCENT
),O
would,O
increase,O
from,O
0.30.7,PERCENT
%,PERCENT
(,O
4951,PERCENT
%,PERCENT
),O
to,O
0.30.8,PERCENT
%,PERCENT
(,O
4852,PERCENT
%,PERCENT
),O
.,O
Thus,O
.,O
changes,O
are,O
minimal,O
and,O
we,O
therefore,O
conclude,O
that,O
our,O
prevalence,O
estimates,O
will,O
be,O
precise,O
.,O
Currently,DATE
.,O
there,O
is,O
only,O
a,O
limited,O
number,O
of,O
reliable,O
serologic,O
tests,O
available,O
.,O
By,O
using,O
the,O
to,O
our,O
knowledge,O
best,O
currently,DATE
available,O
serology,O
test,O
system,O
with,O
IVD,O
certification,O
in,O
the,O
study,O
.,O
the,O
number,O
of,O
valid,O
results,O
will,O
be,O
maximized,O
as,O
compared,O
to,O
other,O
less,O
mature,O
testing,O
systems,O
.,O
Still,O
.,O
with,O
very,O
low,O
sero,O
‐,O
prevalence,O
.,O
the,O
false,O
positive,O
rates,O
in,O
the,O
population,O
might,O
be,O
in,O
the,O
range,O
of,O
the,O
test,O
‐,O
background,O
.,O
All,O
currently,DATE
performed,O
studies,O
face,O
this,O
limi,O
‐,O
tation,O
.,O
However,O
.,O
by,O
repeating,O
visits,O
.,O
the,O
seroconversions,O
will,O
be,O
confirmed,O
.,O
thus,O
offering,O
much,O
better,O
data,O
than,O
mere,O
sero,O
‐,O
preva,O
‐,O
lence,O
data,O
.,O
In,O
addition,O
.,O
it,O
has,O
not,O
yet,O
been,O
established,O
that,O
seropositivity,O
in,O
ELISA,ORGANIZATION
reliably,O
corresponds,O
to,O
immunity,O
.,O
Thus,O
further,O
testing,O
such,O
as,O
virus,O
neutralization,O
is,O
performed,O
for,O
questionable,O
cases,O
.,O
As,O
serology,O
only,O
allows,O
the,O
detection,O
of,O
in,O
‐,O
fection,O
in,O
retrospect,O
.,O
the,O
pharyngeal,O
swab,O
is,O
essential,O
to,O
pick,O
up,O
acute,O
infections,CAUSE_OF_DEATH
.,O
This,O
also,O
allows,O
to,O
detect,O
subjects,O
with,O
symptomatic,O
disease,CAUSE_OF_DEATH
who,O
possibly,O
never,O
develop,O
positive,O
serology,O
;,O
although,O
it,O
is,O
currently,DATE
believed,O
that,O
most,O
patients,O
will,O
develop,O
positive,O
serology,O
within,O
10,DURATION
days,DURATION
after,O
onset,O
of,O
symptoms,O
.,O
Be,O
‐,O
sides,O
.,O
the,O
swab,O
can,O
be,O
used,O
to,O
extract,O
viral,O
RNA,MISC
and,O
used,O
for,O
se,O
‐,O
quencing,O
.,O
offering,O
further,O
information,O
about,O
transmission,O
dynam,O
‐,O
ics,O
within,O
households,O
.,O
quarters,O
or,O
even,O
worldwide,O
.,O
In,O
a,O
pandemic,O
situation,O
.,O
it,O
would,O
neither,O
be,O
ethical,O
nor,O
feasible,O
to,O
use,O
medi,O
‐,O
cal,O
doctors,O
for,O
epidemiological,O
field,O
work,O
as,O
they,O
are,O
needed,O
for,O
clinical,O
service,O
.,O
Therefore,O
.,O
experienced,O
medical,O
students,O
togeth,O
‐,O
er,O
with,O
students,O
of,O
other,O
subjects,O
perform,O
the,O
field,O
work,O
of,O
this,O
study,O
.,O
The,O
medical,O
students,O
involved,O
are,O
not,O
removed,O
from,O
other,O
important,O
tasks,O
during,O
the,O
pandemic,O
.,O
Ethical,MISC
Radon,MISC
et,O
al,O
.,O
BMC,O
Public,ORGANIZATION
Health,ORGANIZATION
considerations,O
are,O
also,O
relevant,O
for,O
the,O
use,O
of,O
personal,O
protective,O
equipment,O
in,O
this,O
study,O
.,O
Currently,DATE
.,O
personal,O
protective,O
equipment,O
is,O
available,O
at,O
Munich,CITY
hospitals,O
.,O
Its,O
availability,O
is,O
being,O
re,O
‐,O
evaluated,O
regularly,O
over,O
the,O
duration,O
of,O
the,O
field,O
work,O
and,O
the,O
demand,O
for,O
personal,O
protective,O
equipment,O
in,O
clinical,O
services,O
will,O
always,O
have,O
KoCo19,O
is,O
a,O
unique,O
possi,O
‐,O
bility,O
to,O
obtain,O
more,O
reliable,O
estimates,O
of,O
the,O
spread,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
the,O
general,TITLE
population,O
and,O
to,O
better,O
understand,O
the,O
dy,O
‐,O
namics,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Although,O
a,O
single,O
epidemiologic,O
cohort,O
study,O
in,O
one,NUMBER
city,O
will,O
not,O
be,O
able,O
to,O
answer,O
all,O
questions,O
related,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
;,O
it,O
will,O
provide,O
an,O
important,O
epidemiological,O
basis,O
for,O
our,O
understanding,O
of,O
the,O
epidemic,O
.,O
and,O
might,O
serve,O
as,O
a,O
blue,O
‐,O
print,O
for,O
similar,O
studies,O
.,O
COVID,O
‐,O
19,NUMBER
:,O
Corona,O
Virus,O
Disease,CAUSE_OF_DEATH
19,NUMBER
;,O
EDTA,O
:,O
Ethylenediaminetetraacetic,O
Acid,O
;,O
ELISA,PERSON
:,O
Enzyme,O
‐,O
linked,O
Im,O
‐,O
munoassay,O
;,O
Ig,O
:,O
Immunoglobulin,O
;,O
KoCo19,O
:,O
COVID,O
‐,O
19,NUMBER
Acid,O
;,O
RT,O
‐,O
PCR,O
:,O
Re,O
‐,O
verse,O
Transcription,ORGANIZATION
Polymerase,ORGANIZATION
Chain,ORGANIZATION
Reaction,ORGANIZATION
;,O
SARS,O
‐,O
CoV2,O
:,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,NUMBER
;,O
WHO,O
:,O
World,O
Health,O
We,O
thank,O
the,O
KoCo19,O
advisory,O
board,O
Prof.,TITLE
Dr.,O
Stefan,PERSON
Endres,PERSON
.,O
Prof.,TITLE
Dr.,O
Matthias,PERSON
Tschp,PERSON
.,O
Prof.,TITLE
Dr.,O
Andreas,PERSON
Zapf,PERSON
.,O
Prof.,TITLE
Dr.,O
Manfred,PERSON
Wildner,PERSON
.,O
and,O
Stefanie,PERSON
Jacobs,PERSON
.,O
We,O
thank,O
Accenture,PERSON
for,O
the,O
pro,O
‐,O
bono,O
development,O
of,O
the,O
the,O
German,NATIONALITY
Armed,O
Foces,O
(,O
Bundeswehr,ORGANIZATION
),O
for,O
their,O
support,O
.,O
We,O
are,O
grateful,O
to,O
our,O
students,O
at,O
the,O
KoCo19,O
coordina,O
‐,O
tion,O
office,O
:,O
Jan,PERSON
Marius,PERSON
Bruger,PERSON
.,O
Simon,PERSON
Michael,PERSON
Winter,PERSON
Jared,PERSON
Ander,PERSON
‐,PERSON
son,O
;,O
our,O
teams,O
of,O
field,O
workers,O
:,O
Paula,PERSON
Matcau,PERSON
.,O
Norah,PERSON
Kreider,PERSON
.,O
Em,O
‐,O
ma,PERSON
Dech,PERSON
.,O
Laura,PERSON
Charlotte,PERSON
Dech,PERSON
.,O
Tim,PERSON
‐,PERSON
Oliver,PERSON
Haselwarter,PERSON
.,O
Julian,PERSON
Ullrich,PERSON
.,O
Isabel,PERSON
Klugherz,PERSON
.,O
Kristina,PERSON
Gillig,PERSON
.,O
Kerstin,PERSON
Puchinger,PERSON
.,O
Michael,PERSON
Hfinger,PERSON
.,O
Tobias,PERSON
Wrfel,PERSON
.,O
Julius,PERSON
Raschka,PERSON
.,O
Stefan,PERSON
Hillmann,PERSON
.,O
Alexander,PERSON
Maczka,PERSON
.,O
Konstantin,PERSON
Pusl,PERSON
.,O
Isabel,ORGANIZATION
Brand,ORGANIZATION
.,O
Philine,PERSON
Falk,PERSON
.,O
Alisa,PERSON
Markgraf,PERSON
.,O
Stefanie,PERSON
Fischer,PERSON
.,O
Clemens,PERSON
Lang,PERSON
.,O
Magdalena,PERSON
Lang,PERSON
.,O
Silvan,PERSON
Lange,PERSON
.,O
Claire,PERSON
‐,PERSON
Sophie,PERSON
Pleimelding,PERSON
.,O
Leonie,PERSON
Pattard,PERSON
.,O
Tim,PERSON
Hof,PERSON
‐,PERSON
berger,O
.,O
Sonja,PERSON
Magdalena,PERSON
Gauder,PERSON
.,O
Marius,PERSON
Gasser,PERSON
.,O
Vitus,PERSON
Maximilian,PERSON
Grauvogl,PERSON
.,O
Marco,PERSON
Scholz,PERSON
.,O
Hannah,PERSON
Maria,PERSON
Mller,PERSON
.,O
Jonathan,PERSON
Leon,PERSON
Frese,PERSON
.,O
Valeria,PERSON
Baldassarre,PERSON
.,O
Charlotte,PERSON
Kiani,PERSON
.,O
Anna,PERSON
Ngoc,PERSON
‐,O
Nhu,O
Do,O
.,O
Sophie,PERSON
Schultz,PERSON
.,O
Ekaterina,PERSON
Lapteva,PERSON
.,O
Tim,PERSON
Haselwarter,PERSON
.,O
Maximilian,PERSON
Baumann,PERSON
.,O
Elias,PERSON
Golschan,PERSON
.,O
Vitus,PERSON
Grauvogel,PERSON
.,O
Vera,PERSON
Britz,PERSON
.,O
Eva,PERSON
Thumser,PERSON
.,O
Paul,PERSON
Schandelmaier,O
.,O
Patrick,PERSON
Wustrow,PERSON
.,O
Lea,PERSON
Zuche,PERSON
.,O
Janna,PERSON
Hoefflin,PERSON
.,O
Jeni,PERSON
Tang,PERSON
.,O
Julia,PERSON
Wolff,PERSON
.,O
Rebecca,PERSON
Bhnlein,PERSON
.,O
Flora,PERSON
Deak,PERSON
.,O
Lara,PERSON
Schneider,PERSON
.,O
Jakob,PERSON
Reich,PERSON
.,O
Leonard,PERSON
Gilberg,PERSON
.,O
Matthias,PERSON
Hermann,PERSON
.,O
Thomas,PERSON
Zimmer,PERSON
‐,O
mann,O
.,O
Friedrich,PERSON
Caroli,PERSON
.,O
Niklas,PERSON
Thur,PERSON
.,O
Felix,PERSON
Lindner,PERSON
and,O
our,O
tele,O
‐,O
phone,O
interviewers,O
:,O
Nicole,PERSON
Schfer,PERSON
.,O
Julia,PERSON
Waibel,PERSON
.,O
Pia,PERSON
Wullinger,PERSON
.,O
#,O
KoCo19,O
Collaborators,O
are,O
Division,O
of,O
Infectious,O
Diseases,CAUSE_OF_DEATH
and,O
Tropical,MISC
Medicine,MISC
:,O
Abhishek,PERSON
Bakuli,PERSON
.,O
Judith,PERSON
Eckstein,PERSON
.,O
Gnter,PERSON
Froeschl,PERSON
.,O
Otto,PERSON
Geisenberger,PERSON
.,O
Christof,PERSON
Geldmacher,PERSON
.,O
Arlett,PERSON
Heiber,PERSON
.,O
Larissa,PERSON
Hoffmann,PERSON
.,O
Kristina,PERSON
Huber,PERSON
.,O
Dafni,PERSON
Metaxa,PERSON
.,O
Michel,PERSON
Pletschette,PERSON
.,O
Camilla,PERSON
Rothe,PERSON
.,O
Mirjam,PERSON
Schunk,PERSON
.,O
Claudia,PERSON
Wallrauch,PERSON
.,O
Thorbjrn,PERSON
Zimmer,PERSON
.,O
Helmholtz,ORGANIZATION
Zentrum,ORGANIZATION
Mnchen,O
:,O
Mathematics,O
and,O
Life,O
Sciences,O
),O
.,O
Reiner,PERSON
Leidl,PERSON
(,O
also,O
affiliated,O
at,O
:,O
Munich,ORGANIZATION
Center,ORGANIZATION
of,O
Health,ORGANIZATION
Sciences,ORGANIZATION
.,O
Ludwig,PERSON
MH,O
is,O
the,O
principal,TITLE
investigator,TITLE
of,O
the,O
study,O
and,O
obtained,O
the,O
necessary,O
funds,O
.,O
Together,O
with,O
KR,O
and,O
ES,O
.,O
MH,O
designed,O
the,O
study,O
and,O
wrote,O
the,O
study,O
protocol,O
.,O
MP,O
.,O
JMGN,O
.,O
IK,O
.,O
LO,O
.,O
FR,O
and,O
VT,STATE_OR_PROVINCE
conceptualized,O
the,O
field,O
work,O
and,O
.,O
together,O
with,O
MD,STATE_OR_PROVINCE
.,O
FF,O
and,O
AW,O
.,O
made,O
significant,O
contributions,O
to,O
the,O
study,O
proto,O
‐,O
col.,TITLE
MD,STATE_OR_PROVINCE
is,O
responsible,O
for,O
the,O
conception,O
of,O
all,O
IT,O
related,O
study,O
components,O
.,O
FF,O
is,O
coordinating,O
the,O
data,O
management,O
and,O
together,O
with,O
MD,STATE_OR_PROVINCE
significantly,O
contributing,O
to,O
data,O
acquisition,O
.,O
FT,O
con,O
‐,O
ceptualizes,O
the,O
modelling,O
of,O
the,O
spread,O
and,O
dynamics,O
of,O
the,O
dis,O
‐,O
ease,O
.,O
AW,O
is,O
responsible,O
for,O
the,O
development,O
and,O
design,O
of,O
all,O
laboratory,O
methods,O
of,O
KoCo19,O
.,O
All,O
submitted,O
version,O
of,O
the,O
paper,O
.,O
They,O
all,O
have,O
agreed,O
to,O
be,O
personally,O
related,O
to,O
the,O
accuracy,O
or,O
integrity,O
of,O
any,O
part,O
of,O
the,O
work,O
.,O
even,O
ones,O
in,O
resolved,O
and,O
the,O
resolution,O
documented,O
in,O
the,O
literature,O
.,O
This,O
project,O
is,O
funded,O
by,O
the,O
Bavarian,MISC
State,ORGANIZATION
Ministry,ORGANIZATION
of,ORGANIZATION
Science,ORGANIZATION
and,O
Art,O
.,O
the,O
LMU,ORGANIZATION
Klinikum,PERSON
Mnchen,PERSON
and,O
Helmholtz,PERSON
Zentrum,PERSON
Mnchen,PERSON
.,O
The,O
funding,O
bodies,O
do,O
not,O
play,O
a,O
role,O
in,O
the,O
design,O
of,O
the,O
study,O
and,O
collection,O
.,O
analysis,O
.,O
Availability,O
of,O
data,O
and,O
materials,O
Not,O
applicable,O
.,O
Ethics,O
approval,O
and,O
consent,O
to,O
participate,O
2020,DATE
.,O
number,O
20275,NUMBER
),O
.,O
Written,O
informed,O
consent,O
is,O
sought,O
from,O
all,O
participants,O
.,O
In,O
case,O
of,O
minors,O
between,O
the,O
ages,O
of,O
8,NUMBER
and,O
17,DURATION
years,DURATION
.,O
participants,O
and,O
their,O
legal,O
guardian,O
(,O
s,O
),O
are,O
asked,O
for,O
written,O
informed,O
consent,O
.,O
For,O
children,O
below,O
the,O
age,O
of,O
8,DURATION
years,DURATION
.,O
written,O
informed,O
consent,O
is,O
sought,O
from,O
the,O
legal,O
guardian,O
(,O
s,O
),O
.,O
The,O
pseudonymization,O
of,O
the,O
data,O
enables,O
us,O
to,O
provide,O
the,O
participants,O
with,O
individualized,O
results,O
.,O
Personal,O
identifying,O
information,O
is,O
stored,O
in,O
a,O
pass,O
‐,O
word,O
‐,O
protected,O
database,O
containing,O
only,O
contact,O
details,O
.,O
contact,O
status,O
and,O
contact,O
IDs,O
.,O
The,O
data,O
for,O
each,O
questionnaire,O
response,O
and,O
the,O
other,O
samples,O
are,O
stored,O
in,O
a,O
separate,O
password,O
‐,O
protected,O
database,O
containing,O
only,O
ID,STATE_OR_PROVINCE
numbers,O
.,O
It,O
is,O
therefore,O
not,O
possible,O
to,O
draw,O
any,O
conclusions,O
about,O
the,O
identity,O
of,O
the,O
participants,O
and,O
the,O
information,O
they,O
have,O
provided,O
.,O
Compliance,O
with,O
data,O
pro,O
‐,O
tection,O
regulations,O
was,O
approved,O
by,O
the,O
Gerhard,PERSON
Meyer,PERSON
.,O
The,O
data,O
are,O
stored,O
for,O
as,O
long,O
as,O
they,O
are,O
needed,O
to,O
achieve,O
the,O
study,O
objectives,O
.,O
Ten,DURATION
years,DURATION
after,O
the,O
start,O
of,O
the,O
study,O
(,O
and,O
every,O
three,DURATION
years,DURATION
thereafter,O
),O
.,O
the,O
study,O
team,O
will,O
evaluate,O
whether,O
the,O
study,O
objectives,O
for,O
the,O
project,O
have,O
been,O
achieved,O
and,O
.,O
if,O
so,O
.,O
will,O
request,O
the,O
deletion,O
of,O
all,O
personal,O
data,O
.,O
Consent,O
for,O
pub,O
‐,O
lication,O
Not,O
applicable,O
.,O
Competing,O
interests,O
Ziemssenstr,PERSON
.,O
1,NUMBER
.,O
80336,NUMBER
Munich,CITY
.,O
Germany,COUNTRY
.,O
2Center,O
for,O
International,ORGANIZATION
Health,ORGANIZATION
.,O
Leopold,PERSON
‐,PERSON
strasse,O
5,NUMBER
.,O
80802,NUMBER
Munich,CITY
.,O
Germany,COUNTRY
.,O
4German,O
Center,O
for,O
Infection,CAUSE_OF_DEATH
Research,O
(,O
DZIF,O
),O
.,O
partner,O
site,O
Munich,CITY
.,O
Munich,CITY
.,O
Germany,COUNTRY
.,O
5Helmholtz,O
Zentrum,PERSON
Mnchen,PERSON
.,O
Ingolstdter,ORGANIZATION
Landstrae,ORGANIZATION
1,NUMBER
.,O
85764,NUMBER
Neuherberg,O
.,O
Ger,O
‐,O
many,O
.,O
Medicine,O
.,O
LMU,ORGANIZATION
of,O
Munich,CITY
.,O
Munich,CITY
.,O
Germany,COUNTRY
.,O
Radon,O
et,O
al,O
.,O
BMC,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
1,NUMBER
.,O
Sohrabi,O
C,O
.,O
Alsafi,PERSON
Z,PERSON
.,O
O’Neill,O
N,O
.,O
Khan,PERSON
M,O
.,O
Ker,PERSON
‐,PERSON
wan,O
A,O
.,O
Al,O
‐,O
Jabir,O
A,O
.,O
et,O
al,O
.,O
World,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Int,PERSON
J,PERSON
Surg,O
.,O
2020,DATE
;,O
76:716,NUMBER
.,O
2,NUMBER
.,O
Rothe,PERSON
C,O
.,O
Schunk,PERSON
M,O
.,O
Sothmann,O
P,O
.,O
Bretzel,PERSON
G,PERSON
.,O
Froeschl,O
G,O
.,O
Wallrauch,PERSON
C,PERSON
.,O
et,O
al,O
.,O
Transmission,O
of,O
2019,DATE
‐,O
nCoV,O
infec,O
‐,O
tion,O
from,O
an,O
asymptomatic,O
contact,O
in,O
Germany,COUNTRY
.,O
N,O
Engl,PERSON
J,PERSON
Med,PERSON
.,O
2020,DATE
;,O
382,NUMBER
(,O
10,NUMBER
),O
:,O
9701,DATE
.,O
3,NUMBER
.,O
Wolfel,PERSON
R,PERSON
.,O
Corman,PERSON
VM,PERSON
.,O
Guggemos,PERSON
W,PERSON
.,O
Seilmaier,PERSON
M,O
.,O
Zange,PERSON
S,PERSON
.,O
Muller,PERSON
MA,PERSON
.,O
et,O
al,O
.,O
Virological,O
assessment,O
of,O
hospi,O
‐,O
talized,O
patients,O
with,O
COVID,O
‐,O
2019,DATE
.,O
Nature,O
.,O
4,NUMBER
.,O
Robert,PERSON
Koch,PERSON
Insti,PERSON
‐,PERSON
tut,O
.,O
COVID,O
‐,O
19,NUMBER
:,O
Fallzahlen,O
in,O
Deutschland,COUNTRY
und,O
weltweit,O
.,O
Coron,PERSON
‐,O
avirus/Fallzahlen.html,O
.,O
Accessed,O
8,DATE
May,DATE
2020,DATE
.,O
5,NUMBER
.,O
Enserink,O
M,O
.,O
Kupferschmidt,O
K.,O
With,O
COVID,O
‐,O
19,NUMBER
.,O
modeling,O
takes,O
on,O
life,O
and,O
death,O
importance,O
.,O
Science,O
.,O
2020,DATE
;,O
367,NUMBER
(,O
6485,NUMBER
),O
:,O
14145,NUMBER
.,O
6,NUMBER
.,O
Wu,PERSON
JT,PERSON
.,O
Leung,PERSON
K,PERSON
.,O
Leung,PERSON
GM,O
.,O
Nowcasting,O
and,O
forecasting,O
the,O
potential,O
domestic,O
and,O
international,O
spread,O
of,O
the,O
2019,DATE
‐,O
nCoV,O
outbreak,O
originating,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
modelling,O
study,O
.,O
Lancet,O
.,O
2020,DATE
;,O
395,NUMBER
(,O
10225,NUMBER
),O
:,O
68997,NUMBER
.,O
8,NUMBER
.,O
Verity,ORGANIZATION
R,ORGANIZATION
.,O
Okell,ORGANIZATION
LC,ORGANIZATION
.,O
Dorigatti,PERSON
I,O
.,O
Winskill,PERSON
P,O
.,O
Whittaker,PERSON
C,O
.,O
Imai,PERSON
N,O
.,O
et,O
al,O
.,O
Estimates,O
of,O
the,O
severity,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
a,O
model,TITLE
‐,O
based,O
analysis,O
.,O
Lancet,O
Infect,O
Dis,O
.,O
2020,DATE
.,O
9,NUMBER
.,O
Ciotti,PERSON
M,O
.,O
Angeletti,PERSON
S,O
.,O
Minieri,PERSON
M,O
.,O
Giovannetti,PERSON
M,O
.,O
Benvenuto,PERSON
D,PERSON
.,O
Pascarella,PERSON
S,O
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
Outbreak,O
:,O
An,O
Overview,O
.,O
Chemotherapy,O
.,O
2020:19,NUMBER
.,O
10,NUMBER
.,O
Boccia,PERSON
S,O
.,O
Ricciardi,PERSON
W,PERSON
.,O
Ioannidis,ORGANIZATION
JPA,ORGANIZATION
.,O
What,O
other,O
countries,O
can,O
learn,O
from,O
Italy,COUNTRY
during,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
JAMA,O
Intern,TITLE
Med,O
.,O
2020,DATE
.,O
11,NUMBER
.,O
Mavragani,O
A.,O
Tracking,O
COVID,O
‐,O
19,NUMBER
in,O
Europe,LOCATION
:,O
an,O
In,O
‐,O
fodemiology,O
study,O
.,O
JMIR,ORGANIZATION
Public,ORGANIZATION
Health,ORGANIZATION
Surveill,ORGANIZATION
.,O
2020,DATE
.,O
12,NUMBER
.,O
Liv,PERSON
‐,PERSON
ingston,O
E,O
.,O
Bucher,PERSON
K.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
Italy,COUNTRY
.,O
JAMA,ORGANIZATION
.,O
13,NUMBER
.,O
Khafaie,PERSON
MA,PERSON
.,O
Rahim,PERSON
F.,PERSON
Cross,PERSON
‐,O
country,O
comparison,O
of,O
case,O
fatality,O
rates,O
of,O
COVID,O
‐,O
19,NUMBER
/,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
Osong,PERSON
Public,PERSON
Health,ORGANIZATION
Res,ORGANIZATION
Perspect,ORGANIZATION
.,O
2020,DATE
;,O
11,NUMBER
(,O
2,NUMBER
),O
:,O
7480,DATE
.,O
14,NUMBER
.,O
Ferguson,ORGANIZATION
NM,ORGANIZATION
.,O
Laydon,PERSON
D,PERSON
.,O
Nedjati,O
‐,O
Gilani,PERSON
G,PERSON
.,O
Imai,PERSON
N,O
.,O
Baguelin,LOCATION
M,O
.,O
Bhatia,PERSON
S,O
.,O
et,O
al,O
.,O
Report,O
9,NUMBER
:,O
impact,O
of,O
non,O
‐,O
pharmaceutical,O
interventions,O
(,O
NPIs,O
),O
to,O
reduce,O
COVID,O
‐,O
19,NUMBER
mortality,O
and,O
healthcare,O
demand,O
.,O
London,CITY
:,O
Imperial,O
Col,O
‐,O
lege,O
;,O
2020,DATE
.,O
15,NUMBER
.,O
Korean,NATIONALITY
Society,MISC
of,MISC
Infectious,MISC
D,O
.,O
Korean,ORGANIZATION
Society,ORGANIZATION
of,O
Pediatric,O
Infectious,O
D,O
.,O
Korean,NATIONALITY
Society,O
of,O
E,O
.,O
Korean,ORGANIZATION
Society,ORGANIZATION
for,O
Antimicrobial,O
T,O
.,O
Korean,ORGANIZATION
Society,ORGANIZATION
for,ORGANIZATION
Healthcare,ORGANIZATION
‐,O
associated,O
In,O
‐,O
fection,O
C,O
.,O
Prevention,O
.,O
et,O
al,O
.,O
Report,O
on,O
the,O
Epidemiological,O
Fea,O
‐,O
tures,O
of,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Outbreak,O
dynamics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
Korea,COUNTRY
:,O
based,O
on,O
mathematical,O
modeling,O
and,O
simulation,O
study,O
.,O
J,MISC
Korean,NATIONALITY
Med,MISC
Sci,MISC
.,O
2020,DATE
;,O
35,NUMBER
(,O
13,NUMBER
),O
:,O
e143,O
.,O
17,NUMBER
.,O
An,O
der,O
Heiden,PERSON
M,O
.,O
Buchholz,PERSON
U.,PERSON
Modellierung,PERSON
von,PERSON
Beispielszenarien,PERSON
der,PERSON
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
‐,O
Epidemie,O
2020,DATE
in,O
Deutschland,COUNTRY
;,O
2020,DATE
.,O
18,NUMBER
.,O
Grill,O
E,O
.,O
Rothenbacher,PERSON
D.,PERSON
Stellungnahme,PERSON
der,O
Deutschen,ORGANIZATION
Gesellschaft,ORGANIZATION
fr,O
Epi,O
‐,O
demiologie,O
(,O
DGEpi,O
),O
zur,O
Verbreitung,O
des,O
neuen,O
Coronavirus,O
(,O
SARS,O
‐,O
CoV2,O
),O
.,O
Ulm,O
:,O
Deutsche,ORGANIZATION
Gesellschaft,ORGANIZATION
fr,O
Epidemiologie,O
;,O
2020,DATE
.,O
19,NUMBER
.,O
Jefferson,PERSON
T,O
.,O
Del,ORGANIZATION
Mar,ORGANIZATION
CB,ORGANIZATION
.,O
Dooley,PERSON
L,O
.,O
Ferroni,O
E,O
.,O
Al,O
‐,O
Ansary,O
LA,O
.,O
Bawazeer,ORGANIZATION
GA,ORGANIZATION
.,O
et,O
al,O
.,O
Physical,O
interventions,O
to,O
interrupt,O
or,O
reduce,O
the,O
spread,O
of,O
respiratory,O
viruses,O
.,O
Cochrane,ORGANIZATION
Database,ORGANIZATION
Syst,ORGANIZATION
Rev.,TITLE
2011,DATE
;,O
7,NUMBER
:,O
CD006207,O
.,O
20,NUMBER
.,O
Ioannidis,ORGANIZATION
JPA,ORGANIZATION
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
the,O
harms,O
of,O
exaggerated,O
information,O
and,O
non,O
‐,O
evidence,O
‐,O
based,O
mea,O
‐,O
sures,O
.,O
Eur,PERSON
J,PERSON
Clin,PERSON
Invest,PERSON
.,O
2020,DATE
:,O
21,NUMBER
.,O
Venkatesh,MISC
A,MISC
.,O
Edirappuli,PERSON
S.,PERSON
Social,O
distancing,O
in,O
covid,O
‐,O
19,NUMBER
:,O
what,O
are,O
the,O
mental,O
health,O
impli,O
‐,O
cations,O
?,O
BMJ,O
.,O
2020,DATE
;,O
369,NUMBER
:,O
m1379,O
.,O
22,NUMBER
.,O
Gupta,PERSON
M,O
.,O
Abdelmaksoud,PERSON
A,O
.,O
Jaf,O
‐,O
ferany,O
M,O
.,O
Lotti,PERSON
T,O
.,O
Sadoughifar,PERSON
R,PERSON
.,O
Goldust,O
M.,O
COVID,O
‐,O
19,NUMBER
and,O
Econo,MISC
‐,O
my,O
.,O
Dermatol,O
Ther,O
.,O
2020,DATE
:,O
e13329,O
.,O
.,O
23,NUMBER
.,O
Bong,ORGANIZATION
CL,ORGANIZATION
.,O
Brasher,PERSON
C,O
.,O
Chikum,O
‐,O
ba,O
E,O
.,O
McDougall,PERSON
R,PERSON
.,O
Mellin,PERSON
‐,O
Olsen,PERSON
J,PERSON
.,O
Enright,PERSON
A,O
.,O
The,O
COVID,O
‐,O
19,NUMBER
pan,O
‐,O
demic,O
:,O
effects,O
on,O
low,O
and,O
middle,O
‐,O
income,O
countries,O
.,O
Anesth,PERSON
24,NUMBER
.,O
Chowell,PERSON
G,PERSON
.,O
Mizumoto,PERSON
K,PERSON
.,O
The,O
COVID,O
‐,O
19,NUMBER
pandemic,O
in,O
the,O
USA,COUNTRY
:,O
what,O
might,O
we,O
expect,O
?,O
Lancet,O
.,O
2020,DATE
;,O
395,NUMBER
(,O
10230,NUMBER
),O
:,O
10934,NUMBER
.,O
25,NUMBER
.,O
Adam,PERSON
D.,PERSON
Spe,PERSON
‐,PERSON
cial,O
report,O
:,O
the,O
simulations,O
driving,O
the,O
world,O
’s,O
response,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
Nature,O
.,O
2020,DATE
.,O
26,NUMBER
.,O
Lipsitch,O
M,O
.,O
Swerdlow,PERSON
DL,O
.,O
Finelli,PERSON
L.,PERSON
Defining,O
the,O
epidemiology,O
of,O
Covid,O
‐,O
19,NUMBER
studies,O
needed,O
.,O
N,O
Engl,PERSON
J,PERSON
Med,O
.,O
2020,DATE
;,O
382,NUMBER
(,O
13,NUMBER
),O
:,O
119496,NUMBER
.,O
27,NUMBER
.,O
Landeshauptstadt,PERSON
Mnchen,PERSON
.,O
Statis,O
‐,O
tisches,O
Amt,O
:,O
Interaktive,O
Anwendungen,O
rathaus,O
/,O
Stadtinfos,O
/,O
Statis,O
‐,O
tik,O
/,O
Indikatoren,O
‐,O
und,O
‐,O
Monatszahlen.html,O
.,O
Accessed,O
8,NUMBER
28,NUMBER
.,O
Stadt,PERSON
Mnchen,O
.,O
Entwicklung,PERSON
der,O
Coronavirus,O
‐,O
Flle,O
in,O
Mnchen,LOCATION
Munich,CITY
.,O
Stadt,O
‐,O
infos,O
/,O
Coronavirus,O
‐,O
Fallzahlen.html,O
.,O
Accessed,O
8May,DATE
2020,DATE
.,O
29,NUMBER
.,O
Lemeshow,O
S,O
.,O
Robinson,ORGANIZATION
D.,ORGANIZATION
Surveys,ORGANIZATION
to,O
measure,O
programme,O
coverage,O
and,O
on,O
immunization,O
.,O
World,O
Health,O
Stat,O
Q.,O
1985,DATE
;,O
38,NUMBER
(,O
1,NUMBER
),O
:,O
6575,DATE
.,O
30,NUMBER
.,O
Bur,O
‐,O
ney,O
PG,O
.,O
Luczynska,PERSON
C,PERSON
.,O
Chinn,PERSON
S,O
.,O
Jarvis,PERSON
D,O
.,O
The,O
European,NATIONALITY
Community,O
respiratory,O
health,O
survey,O
.,O
Eur,O
Respir,O
J.,O
1994,DATE
;,O
7,NUMBER
(,O
5,NUMBER
),O
:,O
95460,NUMBER
.,O
32,NUMBER
.,O
Schupp,PERSON
J,PERSON
.,O
The,O
socioeconomic,O
panel,O
(,O
SOEP,ORGANIZATION
),O
.,O
Bundesgesundheitsblatt,PERSON
Gesundheitsforschung,PERSON
Gesundheitsschutz,PERSON
.,O
2012,DATE
;,O
55,NUMBER
(,O
67,NUMBER
),O
:,O
76774,NUMBER
.,O
33,NUMBER
.,O
Meisinger,PERSON
C,O
.,O
Peters,PERSON
A,O
.,O
Linseisen,O
J.,O
From,O
the,O
MONICA,O
‐,O
project,O
via,O
KORA,ORGANIZATION
to,O
the,O
NAKO,ORGANIZATION
‐,O
study,O
:,O
practical,O
utility,O
of,O
epidemiological,O
studies,O
in,O
Augsburg,CITY
region,O
.,O
Gesundheitswesen,O
.,O
2016,DATE
;,O
78,NUMBER
(,O
2,NUMBER
),O
:,O
8490,DATE
.,O
34,NUMBER
.,O
Coronavirus,O
in,O
Mnchen,LOCATION
:,O
Die,O
aktuelle,O
Entwicklung,O
Munich,CITY
.,O
Ger,O
‐,O
many,O
:,O
City,O
of,O
coronavirus,O
‐,O
muenchen,O
‐,O
infektion,O
‐,O
aktueller,O
‐,O
stand.html,O
.,O
Accessed,O
8,DATE
May,DATE
2020,DATE
.,O
35,NUMBER
.,O
Schipf,O
S,O
.,O
Schone,PERSON
G,PERSON
.,O
Schmidt,PERSON
B,O
.,O
Gunther,PERSON
K,PERSON
.,O
Stubs,O
G,O
.,O
Greiser,ORGANIZATION
KH,ORGANIZATION
.,O
et,O
al,O
.,O
The,O
baseline,O
assessment,O
of,O
the,O
German,NATIONALITY
National,O
Cohort,O
(,O
NAKO,PERSON
Gesundheitsstudie,PERSON
),O
:,O
partici,O
‐,O
pation,O
in,O
the,O
examination,O
modules,O
.,O
quality,O
assurance,O
.,O
and,O
the,O
use,O
of,O
secondary,O
data,O
.,O
Bundesgesundheitsblatt,PERSON
Gesundheitsforschung,PERSON
Gesundheitsschutz,PERSON
.,O
2020,DATE
;,O
63,NUMBER
(,O
3,NUMBER
),O
:,O
25466,NUMBER
.,O
36,NUMBER
.,O
Weinmann,PERSON
T,O
.,O
Vetter,PERSON
C,O
.,O
Karch,PERSON
S,PERSON
.,O
Nowak,PERSON
D,O
.,O
Radon,O
K.,O
Shift,O
work,O
and,O
cognitive,O
impairment,O
in,O
later,O
life,O
‐,O
results,O
of,O
a,O
cross,O
‐,O
sectional,O
pilot,TITLE
study,O
testing,O
the,O
feasibility,O
of,O
a,O
large,O
‐,O
scale,O
epidemiologic,O
investigation,O
.,O
BMC,O
Public,ORGANIZATION
Health,ORGANIZATION
.,O
37,NUMBER
.,O
Rothman,PERSON
KJ,PERSON
.,O
Gallacher,PERSON
JE,PERSON
.,O
Hatch,PERSON
EE,O
.,O
Why,O
rep,O
‐,O
resentativeness,O
should,O
be,O
avoided,O
.,O
Int,PERSON
J,PERSON
Epidemiol,PERSON
.,O
2013,DATE
;,O
42,NUMBER
(,O
4,NUMBER
),O
:,O
10124,NUMBER
.,O
38,NUMBER
.,O
Weinmann,PERSON
T,O
.,O
AlZahmi,MISC
A,MISC
.,O
Schneck,PERSON
A,O
.,O
Mancera,PERSON
Charry,PERSON
JF,PERSON
.,O
Froschl,PERSON
G,PERSON
.,O
Radon,ORGANIZATION
K.,ORGANIZATION
Population,ORGANIZATION
‐,O
based,O
assessment,O
of,O
health,O
.,O
healthcare,O
utilisation,O
.,O
and,O
specific,O
needs,O
of,O
Syrian,NATIONALITY
mi,O
‐,O
grants,O
in,O
Germany,COUNTRY
:,O
what,O
is,O
the,O
best,O
sampling,O
method,O
?,O
BMC,ORGANIZATION
Med,ORGANIZATION
Res,ORGANIZATION
Methodol,O
.,O
2019,DATE
;,O
19,NUMBER
(,O
1,NUMBER
),O
:,O
5,NUMBER
.,O
39,NUMBER
.,O
Young,O
R,O
.,O
Johnson,PERSON
DR.,O
Handling,O
miss,O
‐,O
ing,O
values,O
in,O
longitudinal,O
panel,O
data,O
with,O
multiple,O
imputation,O
.,O
J,O
Marriage,O
Fam,O
.,O
2015,DATE
;,O
77,NUMBER
(,O
1,NUMBER
),O
:,O
27794,NUMBER
.,O
40,NUMBER
.,O
Julia,PERSON
M,O
.,O
Belvis,PERSON
F,PERSON
.,O
Vives,PERSON
A,O
.,O
Tarafa,PERSON
G,PERSON
.,O
Benach,ORGANIZATION
J.,ORGANIZATION
Informal,ORGANIZATION
employees,O
in,O
the,O
European,ORGANIZATION
Union,ORGANIZATION
:,O
working,O
conditions,O
.,O
employment,O
precariousness,O
and,O
health,O
.,O
J,O
Pub,O
‐,O
lic,O
Health,O
(,O
Oxf,O
),O
.,O
2019,DATE
;,O
41,NUMBER
(,O
2,NUMBER
),O
:,O
e141e51,O
.,O
